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1 Introduction 
1.1 Insights into sterile and non-sterile inflammation 
Tissue damage, either as a result of trauma or infection, triggers a complex inflammatory 
host response that is ultimately responsible for injury resolution and repair and thus for 
patient survival [34, 237]. A prerequisite for this favorable outcome is a well-regulated, 
self-resolving inflammation. The initial host response comprises simultaneously 
occurring inflammatory and anti-inflammatory events that only when balanced result in 
restoration of immune system homeostasis [196, 199, 264]. Tipping this balance in either 
direction results in an inadequate response for the host’s biological needs in form of either 
insufficient or overwhelming inflammation [110, 196, 199]. An overwhelming systemic 
inflammatory response syndrome (SIRS) can progress to shock, multiorgan dysfunction 
and death [135, 149, 154]. An exuberant compensatory anti-inflammatory response (CARS) 
causes immunosuppression with high susceptibility to opportunistic infection and 
subsequent sepsis [35, 196, 199, 264]. 
Until recently, surviving infection and trauma was solely dependent on the host immune 
response, whose intertwined network of mediators and cells was optimized by millions 
of years of evolutionary pressure. Mortality was high, with pandemics throughout history 
known to have decimated up to a third of the world’s population [104]. Modern medical 
therapy though, has made it possible to overcome the early stages of severe infection and 
trauma, allowing the inflammatory process to further unfold. This on the other hand gave 
way to the new challenge of dealing with the consequences of more frequently occurring 
syndromes of immune dysregulation [110, 188, 199]. Despite numerous efforts and 
extensive research including studies on animal models [31, 105, 203] and clinical trials [59, 
76, 230], there is currently no available therapy through which immune homeostasis can 
effectively be achieved. This is why we continue to observe an elevated mortality rate 
due to severe sepsis and trauma complicated with multiorgan dysfunction, which in 
intensive therapy units exceeds 50% [268].  
The main difficulties reside in the complexity of the immune response as well as in the 
failure to translate the so far acquired basic knowledge into therapeutic strategies. Due to 
the complexity of inflammation, explaining the pathway from danger recognition to a 
competent immune reaction or to organ damage has taken a piece-meal approach. 
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Defining mechanisms of inflammation that unify the large dataset generated in preclinical 
and clinical studies remains challenging despite available computational models [188, 231, 
291, 292]. Furthermore, therapeutic success in animal experiments fail to be translated into 
clinical setting because of the difficulties in generating appropriate animal models that 
reflect the complexity of a patient cohort with accompanying variations in age, sex, 
genetic background and comorbidities [188, 232, 244]. 
1.2 Inflammatory response initiation at the site of injury 
The capacity of the immune system to detect invasion by pathogens relies on the initial 
interaction of so-called pathogen-associated molecular patterns (PAMPs) with pattern 
recognition receptors (PRRs) on the surface of immune cells such as macrophages and 
polymorphonuclear cells [32, 202, 237]. This accounts for the first stage of the innate 
immune response that is immediate but non-specific [175]. PAMPs are compounds that 
are produced by groups of related pathogens and that are essential for the pathogen’s 
viability, such as lipopolysaccharide (LPS), lipotheicoic acid or peptidoglycans [32, 116, 
175]. Introducing the danger theory in 1994, Matzinger proposed an analogy to the PAMP-
PPR interaction to explain inflammation induced by sterile injury [172]. According to this, 
endogenous analogues to PAMPs, termed damage-associated molecular patterns 
(DAMPs) bind to the same PPRs initiating the inflammatory process in response to 
trauma [172, 173]. DAMPs are intracellular molecules, such as chromatin-associated high-
mobility group box 1 (HMGB1) [81, 248], heat shock proteins (HSPs) [170], mitochondrial 
DNA [314] and purine metabolites like uric acid, adenosine triphosphate (ATP) and 
adenosine [236] that are released into the extracellular milieu by damaged cells. 
Toll-like receptor 4 (TLR4) was the first PRR to be described, identified as the main 
driver in inflammation regardless of the nature of the stimuli as it can be activated by both 
LPS and HMGB1, the prototypical PAMP and DAMP, respectively [130, 181, 206, 264]. 
Although both ligands are known to bind to TLR4, the inflammatory responses they elicit 
differ in certain respects [41, 130]. Upon LPS recognition, TLR4 triggers intracellular 
signaling pathways resulting in activation of the transcription factors nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-𝜅B) and activator protein 1 (AP-1) 
[146, 198, 205]. This ultimately leads to dendritic cell (DC) maturation and pro-
inflammatory cytokine production. The fully activated DCs provide the link to an 
adaptive immune response by delivering all necessary signals for naive T-cell activation 
[41, 237, 286]. 
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HMGB1 on the other hand not only acts as a PRR agonist but also as a PRR co-receptor 
and chemotactic agent for leukocytes [41, 248]. As a non-histonic chromatin protein 
HMGB1 is passively released by necrotic cells into the extracellular space, where it is 
oxidized. The oxidized HMGB1 can then bind to TLR4 leading to down-stream NF-𝜅B 
activation [72, 92, 130]. The resulting inflammatory response, triggered by cell death in the 
absence of a pathogenic invasion is less potent, and there is little evidence of adaptive 
immunity activation [41, 308]. 
In both sterile and pathogen-associated tissue damage, PRR-mediated activation of 
intracellular signaling pathways in immune cells leads to secretion of cytokines and 
chemokines that propagate the inflammatory process by recruiting further immune cells 
to the site of injury [237, 264, 286]. Already at this stage, the immune response integrates 
positive and negative feedback elements, combining pro- and anti-inflammatory activity 
that will ultimately influence the clinical course of the patient [214].  
1.3 Chemokines and their role in inflammation 
1.3.1 Chemokines and their receptors: an intricate system 
The chemokine system coordinates leukocyte trafficking both under homeostatic and 
altered immune conditions. Local recruitment and timely activation of specific immune 
cell subsets upon pathogen invasion or tissue injury are dependent on the chemokine 
network that till date comprises 50 ligands and their corresponding receptors [18, 36, 95, 
222]. Chemokines are small peptides of 8-12 kDa, that are classified into two major 
subfamilies (CC and CXC) and two minor subfamilies (CX3C and XC) based on the 
positioning of the N-terminal cysteine residues (C represents cysteine and X/X3 one or 
three non-cysteine amino acids) [13, 177, 265, 289]. 20 chemokine receptors that are part of 
the G protein-coupled receptor (GPCR) family are responsible for mediating the 
downstream effects of chemokines and are also classified in 4 subfamilies according to 
the ligands they bind: CCR1-10, CXCR1-6, CX3CR1 and XCR1 [18, 289]. Additionally, 
there are three known scavenger receptors, that reduce chemokine potency by 
internalizing upon ligand binding without further downstream signaling [192, 282].  
As expected of their central chemotactic role, chemokine receptors are found mainly on 
the surface of bone marrow-derived cells. Accounting for their other known roles in 
haematopoesis, apoptosis, angiogenesis, extracellular matrix remodeling, etc., chemokine 
receptors are also expressed on the surface of endothelia, smooth muscle cells, stromal 
CHAPTER 1                                                                                          INTRODUCTION 
 4 
cells, neurons and epithelial cells [87, 265]. 
Based on their function, chemokines can also arbitrarily be classified into inducible and 
constitutive chemokines [87, 289]. Inducible chemokines are produced under inflammatory 
conditions by activated immune cells and are responsible for leukocyte recruitment, 
whereas constitutive chemokines maintain basal leukocyte trafficking responsible for 
immune surveillance and participate in spatial organization of secondary lymphoid organs 
[13, 87, 289]. 
Different types of leukocytes express different patterns of chemokine receptors, enabling 
selective immune cell recruitment on account of the chemokine gradients generated by 
the affected tissue. Despite this apparent selectivity, the chemokine system was generally 
perceived as redundant, since the same chemokine receptor can be expressed by different 
types of leukocytes and can be stimulated by different ligands, that in turn can bind to 
different receptors [18, 163, 270]. This theoretically supports the experimental observation 
that knock-out mice for most of the chemokine receptors have no significant change in 
phenotype [13, 219]. However, more recent data revealed that, although the common 
function of chemotaxis is induced by overlapping chemokine-receptor combinations, 
each ligand receptor pair activates distinct intracellular signaling pathways that deliver 
different functional outcomes, nuancing the known chemotactic effect [249]. For example, 
chemokines CXCL9, -10 and -11 each induce T-cell chemotaxis when binding to the 
same receptor: CXCR3. CXCL11 though, exerts an anti-inflammatory effect by inducing 
the differentiation of regulatory T cells in contrast to CXCL9 and -10 whose effects are 
pro-inflammatory [220, 319]. Explaining this dichotomic functional outcome caused by 
CXCR3 activation are differences in ligand affinity and receptor binding sites, receptor 
internalization and downstream signaling cascades. This attribute of chemokines to 
preferentially activate one of several available downstream pathways when binding to the 
same receptor is known as functional selectivity or biased signaling [14, 224, 225]. Steen et 
al. summarized the known examples of biased signaling in the chemokine system, 
defining three different categories: ligand bias, receptor bias and tissue or cell bias, 
referring to signal variation with the ligand, with the receptor and with the tissue or cell-
type, respectively [14, 225, 262, 320]. Growing evidence supporting the importance of 
selective signaling is gradually replacing the appearance of system redundancy while 
emphasizing context-defined chemokine receptor interactions. 
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1.3.2 Downstream chemokine-receptor signaling 
Chemokine receptors change the conformation of their 7 transmembrane-spanning 
domains upon binding to their cognate ligand, activating further signal transduction 
through either a heterotrimeric (αβγ) G protein or arrestin intermediary [18, 289]. Signaling 
through G proteins implies transition of the Gα subunit from an inactive guanosine 
diphosphate (GDP)-bound to an active guanosine-5'-triphosphate (GTP)-bound complex 
that dissociates from the receptor and from the Gβγ heterodimer [15, 177]. There are four 
known Gα protein classes mediating signal transduction either through phospholipase C 
activation [120] or regulation of cyclic adenosine monophosphate (cAMP) production 
[186]. The Gβγ heterodimer can act either as an inhibitor of the Gα subunit or participate 
as an effector in signaling cascades leading to ion channel regulation or phosphorylation 
of extracellular signal-regulated kinases (ERK) [224, 289]. 
Initially discovered to be involved in receptor desensitization, β-arrestins are now 
attributed a wide range of subsequent effector pathways involving ERK phosphorylation, 
mitogen-activated protein kinase (MAPK) regulation, etc. that ultimately influence 
chemotaxis, apoptotic and anti-apoptotic signaling and receptor trafficking [224, 265]. 
The mechanism through which these molecular signaling pathways effectively translate 
into directional cell migration, allowing leukocytes to follow a chemotactic signal is yet 
to be fully elucidated.  Several observations using time-lapse videomicroscopy have 
clearly shown a polarization of certain leukocytes, including lymphocytes, monocytes, 
natural killer (NK) cells, DCs and granulocytes, that develop distinct morphological and 
functional poles, rendering them capable of moving along the extracellular chemokine 
gradient [71, 193, 246]. These functional poles, termed filopodia on the leading edge of the 
cell and uropod at the rear of the cell, are the result of complex interactions between 
membrane proteins, the actin cytoskeleton and internal signaling pathways [71, 193, 207]. 
As chemokine receptors are evenly distributed across the cellular membrane of the 
leukocyte, the polarized distribution of Gβγ protein subunits is thought to lead through 
several intermediary effector proteins to actin polymerization at the leading end of the 
leukocyte, pushing it forward [80, 121].  
Apart from polarization, this chemokine-mediated reorganization of the actin 
cytoskeleton is further involved in leukocyte adhesion to the endothelial layer followed 
by transendothelial migration, which enables leukocytes to travel and access the sites of 
injury or infection [71, 298, 305]. 
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1.3.3 Establishing chemokine gradients for leukocyte recruitment 
To fulfill their chemoattractant function by establishing gradients that guide circulating 
leukocytes to the injured tissue, chemokines concentrate on the endothelial surface by 
immobilization on glycosaminoglycans (GAGs) and oligomerization [100, 101, 122]. Both 
aspects seem to be critical for the chemotactic function, as experiments using engineered 
variants of chemokines with mutations rendering them incapable of GAG binding or 
oligomer formation, also showed an abrogated chemoattracting potential in vivo [12, 215, 
221]. GAGs are negatively charged carbohydrate structures covalently attached to the core 
protein of proteoglycans, ubiquitously found on the surface of cells and in the 
extracellular matrix. Due to their vast structure variability with particular distribution 
patterns on the surface of various cell types as well as specific affinity for certain 
chemokines, GAGs affect chemokine localization and gradient formation [101]. 
Concentrated on the endothelial surface, chemokines can interact directly with their 
corresponding receptors on the leukocyte membrane, activating the internal signaling 
cascade. This causes the circulating leukocyte to first adhere to the endothelium by rapid 
increase in integrin binding, then to migrate across the endothelial wall into the tissue 
[100, 101, 221]. 
1.3.4 Chemokine-directed leukocyte migration on the example of monocytes 
10% of the circulating leukocytes in human blood are monocytes, a pivotal component of 
the immune system in both steady-state maintenance and first line of defense [17]. Their 
recruitment to the site of injury is crucial for the control and clearance of pathogenic 
microorganisms and cellular debris, modulating the development and resolution of the 
inflammatory response [89, 309]. Their ability during inflammation to mobilize from the 
bone marrow into the bloodstream and then extravasate to distinct tissue sites, where they 
further differentiate into macrophages and DCs relies on chemotactic signals [257]. The 
distinct chemokine receptor expression on their surface allows a phenotypic and 
functional classification of monocytes. 
1) Classical monocytes (cluster of differentiation (CD)14++ CD16-): express high levels 
of CCR2 and of the LPS co-receptor CD14 (CD14++) on their surface. In case of 
inflammatory challenge, these monocytes are recruited from the bone marrow in a 
CCL2/CCL7-dependent manner [277], while during homeostatic conditions 
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monocyte-derived macrophages patrol extravascular tissues, surveying for antigens 
that they transport to draining lymph nodes [115]. 
2) Non-classical monocytes (CD14+ CD16++): express moderate levels of CD14 
(CD14+), lack CCR2, but express high levels of low-affinity IgG receptor CD16++ and 
of chemokine receptor CX3CR1 [317]. These are patrolling monocytes that 
constitutively migrate on the luminal surface of the endothelium, scavenging for 
particles and damaged cells and thus maintaining the endothelial integrity [45]. In 
homeostatic conditions, less than 1% of these monocytes cross the endothelial barrier 
into tissues [16]. 
3) Intermediate monocytes (CD14++ CD16+) with high CD14 and moderate CD16 
expression have also recently been reported, distinguishing themselves from the other 
subgroups by differences in inflammatory cytokine secretion [317, 318]. 
The classical CCR2-equipped monocytes are the ones to engage from the medullary or 
extramedullary haematopoetic sites into travelling towards distant affected tissues [257]. 
Their mobilization depends on the corresponding CCR2 ligands: monocyte chemotactic 
protein 1 (MCP-1) and 3 (MCP-3), alias CCL2 and CCL7 [118, 257, 269, 277]. CCR2-
deficient mice show reduced trafficking of the monocyte subset corresponding to classical 
human monocytes, that in mice are also characterized by high CCR2 expression, as well 
as high expression of the surface protein LY6C (Ly6C++) [144, 145]. The effect is similar 
when deleting either CCL2 or CCL7 which leads to a 40-50% reduction in monocyte 
recruitment [118, 257]. CCL2 is produced by many cell types including endothelial, 
epithelial, smooth muscle cells, fibroblasts etc., but the major source are 
monocytes/macrophages that are activated in the inflammatory milieu [9, 25, 55, 306]. It 
was expected that CCL2, driven through the blood stream from the site of inflammation 
triggers monocyte emigration from the bone marrow. Experimental proof provided by Shi 
et al. [256] indicates though, that bone marrow mesenchymal stem and progenitor cells are 
at least partially responsible for the CCL2 production that mobilizes monocytes and that 
this CCL2 production is induced by circulating low levels of TLR ligands [256]. 
As the primary scope of these mobilized monocytes is to exert their function at the site of 
injury, a correlation between the amount of mobilized, circulating and tissue infiltrating 
monocytes would be intuitive. However, the paradigmatic leukocytosis in inflammatory 
diseases is rather due to an increase in neutrophil numbers than due to monocytosis, and 
the extravasation of monocytes into tissues rather depends on the local barrier condition 
than on the sheer number of circulating monocytic cells [51, 150]. Certain chemokine axes 
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are crucial in coordinating monocyte movement across these physiological barriers, 
underlining their importance in temporal and spatial compartmentalization of the immune 
response [257].  
The multi-step process that monocytes undergo to cross the endothelial barrier starts by 
selectin-mediated capturing of free-circulating monocytes to the vessel wall, followed by 
rolling, adhesion to endothelial cells, postadhesion strengthening, crawling, and finally 
transmigration [88, 108]. Chemokines and their corresponding receptors withhold explicit 
roles during this process of extravasation: CCR1 is responsible for monocyte arrest 
through integrin activation, CCR5 contributes to postadhesion strengthening, while both 
receptors support CCL5-mediated transmigration [257, 296]. The differential involvement 
of these chemokine receptors and their corresponding ligands in monocyte recruitment is 
of importance not only during the acute inflammatory process but also in the constantly 
rising number of chronic diseases, where sustained inflammation is proven to occupy 
center stage in pathogenesis. In murine models of chronic inflammatory diseases such as 
atherosclerosis or multiple sclerosis (MS), manipulating chemokine receptor expression 
or ligand levels can favorably influence outcome [39, 242, 296, 312].  
Having crossed the endothelial barrier and arrived in an inflammatory setting, classical 
monocytes receive microenvironmental cues to differentiate into macrophages and DCs 
that further engage in the inflammatory response [115] by producing high levels of pro-
inflammatory cytokines, such as interleukin (IL)-1β and tumor necrosis factor (TNF)-α. 
In addition, they also exert phagocytic properties, clearing cellular debris and pathogens, 
while activating NK cells through IL-18 production and engaging adaptive immunity 
through antigen presentation [261].  
1.3.5 Beyond the chemotactic role: CCL3, CCL4, CCL5 and their receptors 
As mentioned previously, CCR1 and CCR5 and their respective ligands CCL3, alias 
macrophage inflammatory protein (MIP)-1α, CCL4 (MIP-1β) and CCL5 (regulated on 
activation, normal T cell expressed and secreted, RANTES) exert key functions in 
monocyte chemotaxis and extravasation. Their implicit roles in development, sustenance 
and propagation of acute and chronic inflammation but also autoimmunity has pushed for 
sustained efforts to develop pharmaceutics to modulate their activity. Aside chemotaxis, 
these ligands have been discovered to be much more versatile in function, raising the 
importance of targeted function control.  
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CCR5 is an obligate co-receptor for the human immunodeficiency virus (HIV)-1 
envelope fusion and entry into macrophages and activated T cells [28, 155]. Individuals 
carrying a naturally occurring homozygous CCR5 mutation, accounting for less than 1% 
of the population, are completely resistant to infection with HIV-1 [208]. CCL3, -4, or -5 
binding to CCR5 block HIV-1 entry into the cells. Chemically modified CCL5 and small-
molecule antagonists for CCR5 have proven to be efficient anti-HIV agents in pre-clinical 
trials and also lead to the first anti-chemokine therapy to be approved for clinical use 
[289].  
Concerning tumor biology, chemokines have an implicit role in recruiting immune cells 
to the tumor microenvironment but can also directly target non-immune cells such as 
tumor stem-like cells, stromal and vascular endothelial cells inside the tumor [187]. In 
some types of cancer CCL2, CCL3 and CCL5 promote cancer cell extravasation by 
inducing matrix degradation through induction of increased metalloproteinase secretion 
[239], influence cancer invasiveness by directly targeting endothelial cells and sustain 
cancer cell motility and epithelial-mesenchymal transition once they accessed the 
vasculature [153, 278]. Murine experimental models of cancer showed increased survival 
due to inhibition of tumor angiogenesis and metastasis, when chemokine function was 
targeted, though they also showed that chemokine blockade alone does not suffice as an 
effective anti-tumor therapy [153, 187, 223]. A clinical trial combining a classical 
chemotherapy protocol with CCR2 blockade in patients with boarderline resectable and 
locally advanced pancreatic cancer showed promising results, though on a limited patient 
cohort [197]. 
While inflammation is intrinsic and necessary, it remains positive just as long as it is 
contained. Regulatory mechanisms such as the chemokine system are crucial for 
delivering either a self-resolving or self-maintaining and propagating inflammation. 
Chemokines have a major influence in compartmentalizing the immune response by 
controlling selective immune cell trafficking across different biologic compartments 
(bone marrow, blood, peripheral tissues) and by modulating the function of the immune 
cells inside these compartments. The most prominent differences in immune response 
characteristics are between the blood compartment and the injured tissue, setting the 
barrier between affected and non-affected. Monocytes, as one of the earliest responding 
leukocyte subset, secrete potent pro-inflammatory cytokines such as IL-1β with beneficial 
effect as a local, limited event. As soon as this pro-inflammatory process traverses into 
the blood compartment resulting in high systemic IL-1β levels, there is an increased risk 
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for SIRS and distant tissue damage to develop [149, 154, 261]. This accentuates the 
importance of regulatory mechanisms in preventing this spillage of the local pro-
inflammatory process into the bloodstream. 
1.4 IL-1β: a tightly controlled cytokine 
Monocytes, macrophages and DCs, are among the cell types that produce and secrete 
IL-1β in response to infections and injuries. The role of IL-1β in microbe elimination was 
acknowledged early on, only for further discoveries to gradually set this cytokine at the 
core of the inflammatory process arising not only in infectious disease but also in trauma, 
chronic multifactorial disease and auto-inflammatory conditions [63, 91]. This potent pro-
inflammatory cytokine, generated at the site of immunological challenge, affects cells and 
organs as distant from the site of injury as the hypothalamus, at remarkably low 
concentrations, causing fever, regulating pain threshold, sleep and appetite, coordinating 
cell recruitment and perpetuating the pro-inflammatory cytokine cascade, that can 
potentially lead to tissue damage [63, 82]. 
Considering its potent, pleiotropic and potentially damaging effect, IL-1β bioactivity is 
regulated at the level of its production and maturation, of receptor binding, and of post-
receptor signaling [66]. Production and release into the extracellular environment is a 
multistep process underpinned by several control levels involving synthesis of an inactive 
precursor, pro-IL-1β, which undergoes proteolytic cleavage to mature IL-1β that is 
subsequently secreted [66, 91]. Pro-IL-1β synthesis does not occur in steady-state 
conditions. Instead, several factors signaling danger during an inflammatory challenge, 
such as endotoxins or endogenous cytokines, prime myeloid cells to produce pro-IL-1β 
[234]. This first danger signal is mediated by TLR or tumor necrosis factor receptors 
(TNFRs) leading to NF-κB activation and enhanced transcription then translation of pro-
IL-1β [66, 94]. LPS binding to TLR4 is the classic example for myeloid cell priming, 
widely used in experimental settings to induce pro-IL-1β synthesis. TNF and IL-1β itself 
are equivalent endogenous pro-IL-1β inducers [97, 117].  
A second signal is tipically required for IL-1β maturation through proteolytic cleaveage 
by caspase-1, whose activation is dependent on the assembly of inflammasomes, that are 
multiprotein complexes of the cytosolic compartment [97, 167].  
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1.4.1 Inflammasomes as intracellular inflammation sensors 
The activation of several inflammasomes converge on the end point of caspase-dependent 
cytokine maturation but starts with a differentiated recognition of a wide array of second 
danger signals. This differentiated recognition is due to inflammasomes containing 
different sensor proteins that specifically identify endogenous or exogenous danger 
signals [167]. For example, the nucleotide-binding oligomerization domain (NOD)-like 
receptor (NLR) containing a caspase activating and recruitment domain (CARD) 4 
(NLRC4) sensor protein directly recognizes bacterial flagellin, while absent in melanoma 
2 (AIM2) identifies double-stranded deoxyribonucleic acid (DNA) when initiating 
inflammasome activation [142, 238]. Beside the sensor protein, a classical inflammasome 
contains an adaptor protein (apoptosis-associated speck-like protein containing a CARD 
[ASC]) and a caspase effector [226, 293].  
The NLR family, pyrin domain (PYD) containing 3 (NLRP3) inflammasome is the best 
characterized and most efficient IL-1β producing mechanism in myeloid cells [91]. Its 
cytosolic sensor is a NLR that initiates inflammasome activation in the presence of a large 
array of stimuli, both of exogenous nature such as bacterial toxins, viral nucleic acids, 
fungal products, and of endogenous provenance such as ATP, cholesterol crystals, 
monosodium urate [138]. This links the NLRP3 inflammasome to the most common 
infectious disease such as staphylococcal infection, candidiasis and influenza, as well as 
to some of most challenging clinical entities in modern day medicine like SIRS, 
Alzheimer’s dementia or metabolic stress [96, 99, 126, 165, 316]. The ASC adaptor protein 
connects through its N-terminal PYD and its CARD the NLR sensor to the pro-caspase-1 
effector, whose activation leads to the proteolytic maturation and secretion of IL-1β [97].  
Activation of the NLRP3 inflammasome does not imply direct binding of the sensor 
protein to the enumerated PAMPs and DAMPs. Instead, these varied agents interact with 
receptors on the cell surface or lead to pore formation in the cell membrane inducing an 
array of signals including potassium efflux, elevated levels of reactive oxygen species 
(ROS) or lysosomal destabilization that mediate inflammasome activation [97, 216]. This 
model of inflammasome assembly was verified in the case of ATP, an endogenous 
molecule whose extracellular presence is an indicator of cell injury or stress and which 
induces potassium efflux in myeloid cells when interacting with the purinergic P2X7 
receptor (P2X7R) on their surface [165]. 
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1.4.2 Purinergic signaling in inflammation 
Due to the high energy content of its pyrophosphate bonds, the role of ATP as the energy 
transfer unit of the cell has long been acknowledged. An amount of ATP equivalent to 
ones own body weight is being synthetized daily [275]. A fraction of this is consumed for 
intracellular signaling, as a substrate for kinases or for signal transduction of GPCRs, 
which are by far the most numerous in eukaryotes [111]. This function of ATP as an 
intercellular mediator however, has only recently shifted into focus, concordant with and 
supported by the danger model propagated by Matzinger [50, 172]. The first proposition of 
ATP as an extracellular messenger, responsible for non-adrenergic, non-cholinergic 
neurotransmission was made in the 1970s by Burnstock [43, 44]. The purinergic hypothesis 
remained unpopular until the specific nucleotide receptors were cloned in the 1990 
leading to increasing acceptance of nucleotides as extracellular transmitters [38, 156, 283, 
295]. 
Extracellular ATP is a sensitive indicator of cellular distress and has been shown to reach 
concentrations in the hundred micromolar range at inflammatory sites as opposed to 
healthy tissues, where it remains in a low nanomolar level [24, 211, 302]. These data further 
support the meanwhile well-established role of ATP as a DAMP at inflammatory sites, 
triggering IL-1β maturation. Apart from this, other critical immune events such as 
antigen-driven T-lymphocyte proliferation, neutrophil and macrophage chemotaxis have 
also been shown to rely on purinergic signaling [74, 123].  
Despite the late discovery and protracted acceptance, equivalents to the human purinergic 
ligand-receptor system have even been found in primitive invertebrates, thus placing 
nucleotides among the primordial mediators of cell-to-cell communication [50, 288]. The 
receptor set responsible for extracellular nucleotide recognition comprises two 
subfamilies: the P2Y receptors (P2YRs), which are G protein-coupled metabotropic 
receptors, and the mainly ligand-gated ionotropic P2XRs [4]. While P2YRs interact with 
various nucleotide ligands such as adenosine diphosphate (ADP), uridine diphosphate 
(UDP), uridine-5'-triphosphate (UTP), UDP-glucose, or UDP-galactose, P2XRs 
selectively engage with extracellular ATP [113].  
Several members of the P2XR subclass have been identified on the surface of immune 
cells, their function, in the wider context of metabolic regulation of T-lymphocytes or 
neutrophil extravasation still awaiting more precise definition [160, 304]. The function of 
P2X7R though, has been investigated at length and is well established. It was the discovery 
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of the NLRP3 inflammasome that shed light on the pivotal role of P2X7R, as part of the 
‘two signal model’ of IL-1β production [75, 167]. In its functional state, the P2X7R is a 
trimer, that upon ATP binding undergoes a conformational rearrangement and forms a 
pore that allows the inward flux of Na+ and Ca2+ and the outward flux of K+ [103, 162]. 
The exact molecular mechanism connecting the decrease in intracellular K+ concentration 
to inflammasome activation is still unknown, but it has been suggested that the change in 
the cytosolic microenvironment is what recruits the inflammasome components to the 
vicinity of P2X7R, where they assemble [182]. This suggestion has been strengthened by 
experimental data that co-localized P2X7R and NLRP3 using confocal microscopy and 
co-immunoprecipitation [77]. Several microbial toxins, such as nigericin, are also known 
to activate the inflammasome by causing depletion of intracellular K+, which seems to be 
a necessary and sufficient condition for NLRP3 activation [182]. 
Besides triggering its production, the P2X7R also seems to play a significant role in IL-1β 
release into the extracellular environment. IL-1β lacks an N-terminal secretory sequence 
that would enable it to engage the canonical secretory pathway of the endoplasmatic 
reticulum and Golgi apparatus [243, 250]. Modified lysosomes, exosomes or plasma-
derived microvesicles have been proposed as vehicles for transporting mature IL-1β 
across the cellular membrane, with P2X7 as a key component of these alternative secretory 
routes [62, 217]. The direct interaction of the P2X7R’s intracellular C-terminal tail with 
membrane proteins such as pannexin-1 and connexin-43 hemichannels leads to the 
formation of large-conductance pores allowing the extracellular release of IL-1β  and 
ATP [26, 210]. 
Further experimental proof involving P2X7R in key inflammatory events showed that it 
promotes the expression of several chemokines, such as the major monocyte attractants 
CCL2 and CCL3 [129, 204]. Furthermore, inflammasome activation can also trigger an 
inflammatory form of cell death known as pyroptosis [8, 218, 258]. In this process, 
mediated by caspase-1activity, pores of an estimated diameter of 1.1-2.4 nm are formed 
in the cell membrane, disrupting the cellular ionic gradients and increasing osmotic 
pressure. This leads to an influx of water, causing the cell to swell, then ultimatelly burst, 
spilling its pro-inflamatory content, including caspase-1-cleaved activated cytokines such 
as IL-1β [258]. 
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1.4.3 Clinical significance of IL-1 blockade 
The sheer importance of strict IL-1β control, from inflammasome assembly to receptor 
binding can easily be deduced from disorders with naturally occurring loss of these innate 
regulatory mechanisms. An example are infants born with a deficiency of the IL-1 
receptor antagonist (IL-1RA) known as DIRA, a recessively inherited disease caused by 
loss-of-function mutations in the gene encoding IL-1RA. As a consequence, a severe 
systemic sterile inflammation develops within the first days of life, that proves fatal unless 
treated [229]. In his pioneering work set to characterize the function of IL-1β, Dinarello 
described in 1996 severe adverse effects in patients injected with low nanomolar doses of 
IL-1β such as fever, hypotension, anorexia, myalgias, arthralgias, fatigue and sleep 
disturbances [63].  
The synthesis and clinical use of IL-1β blockers as monotherapeutics were effective in 
selected inflammatory disorders with IL-1β dysregulation at the core of their 
pathogenesis. These so termed ‘autoinflammatory’ syndromes are caused by mutations 
altering the intracellular apparatus involved in IL-1β synthesis and are uniquely 
responsive to IL-1β blockade [128, 169]. The available agents approved for IL-1β 
neutralization in a clinical setting are limited to three pharmaceuticals: Anakinra - the 
recombinant form of the naturally occurring IL-1RA [65], Rinolacept - a soluble IL-1 
decoy receptor [195, 263] and Canakinumab - monoclonal anti-IL-1β antibodies [40, 69]. 
Many other IL-1β blockers are undergoing clinical trials and are pending approval. Their 
efficiency is incontestable in the treatment of autoinflammatory disease, whose distinct 
entities though varied in clinical manifestation all exhibit an elevated IL-1β secretion by 
blood monocytes when compared to healthy individuals [68, 83]. Amongst them the best 
known is familial mediterranean fever, caused by a mutation in the gene encoding for the 
intracellular protein pyrin, that regulates caspase-1 activation and therefore IL-1β 
maturation [48]. 
Selective IL-1β blockade has also proved beneficial in autoimmune disorders, 
ischemia/reperfusion injuries and several other chronic inflammatory disorders [5, 40, 67, 
161]. This is due to intertwined inflammatory pathways and regulatory feedback loops 
binding innate and adaptive immunity, thus generating a continuum of inflammatory and 
immunological diseases. 
To take example on the currently most prevalent and lethal health condition, acute 
ischemic heart disease also involves inflammatory events, that can be beneficially 
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influenced by IL-1β blockade. IL-1β negatively affects cardiac function by directly 
suppressing myocardium contractility and by amplifying local inflammation through 
recruitment of cytokine producing monocytes that contribute to myocardial necrosis. 
Working on experimental models of acute myocardial infarction in mice, Abbate et al. 
obtained beneficial outcomes when blocking IL-1β, during the acute insult as well as 
during the subsequent process of cardiac remodeling [1, 2]. Subsequent clinical trials 
showed a significant improvement of myocardial contractility and relaxation parameters 
as well as of coronary flow reserve and endothelial function after IL-1β blockade with 
Anakinra [3, 285]. 
Recently gathered data depicts inflammatory events as key contributors to the 
pathogenesis of a growing number of clinical entities such as stroke, diabetes, mental 
impairment, hearing loss, amyloidosis, MS; all of which are currently being evaluated for 
therapeutic response to IL-1β blockade [29, 65, 67, 161, 271]. 
Though trial results deliver a solid argument for the clinical use of IL-1β blockers in a 
growing number of inflammatory diseases, some major health issues quintessentially 
characterized by a cytokine storm astonishingly do not benefit from IL-1β blockade. In 
the treatment of sepsis, for example, where IL-1β attenuation was hoped to provide a 
major breakthrough, two phase III trials comparing Anakinra to placebo failed to meet 
the primary endpoint of improved survival [76, 201]. A healthy immune system 
incorporates many IL-1β regulatory mechanisms in order to maintain or reestablish 
immune homeostasis, providing therefore just as many niches for therapeutic IL-1β 
control. These might supply treatment options in disorders with clear IL-1β involvement, 
where currently available IL-1β blockers are inefficient. Therefore, the quest for IL-1β 
modulation is still underway. Recently, a new compound entitled CY-09 was identified 
to directly bind to the NACHT domain of NLRP3 inhibiting its ATPase activity, which 
is essential for NLRP3 oligomerization and inflammasome assembly [119]. The 
advantages over agents directly targeting IL-1β are argued to be an additional inhibition 
of IL-18 production or pyroptosis and lower immunosuppressive side-effects. 
A further alternative for IL-1β control was delivered by the antiinflamatory effect of 
nicotinic agonists, mediated through nicotinic acetylcholine receptors (nAChRs). 
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1.4.4 Cholinergic regulation of IL-1β release 
The first hints that nAChR agonists might exert an anti-inflammatory effect came from 
the simple clinical observation that patients with chronic inflammatory syndromes such 
as rheumatic arthritis or ulcerative colitis benefit from nicotine consumption [11, 27, 52, 
102, 174, 194]. The presence of nAChRs on the surface of immune cells has been reported 
as early as the 1970s and since confirmed by radiolabeled ligand-binding studies [7, 168, 
273], messenger ribonucleic acid (mRNA) expression [179, 247] and immonocytochemical 
analysis. Acetylcholine (ACh) has been established by Dale as the neurotransmitter of the 
cholinergic nervous system and was isolated by him and Dudley from the spleen of oxen 
in 1929 [58]. Earlier even, in 1910, the presence of lymphocytes and their circulation 
through the spleen, a secondary lymphoid tissue, was described [260]. When putting all of 
the above facts together, theories linking the ACh releasing efferents of the vagal nerve 
to the nAChRs of immune cells in the spleen seemed rational. These theories were further 
endorsed by the experimental results of Tracey’s group showing that stimulation of the 
distal end of the vagal nerve dampens the release of pro-inflammatory cytokines such as 
TNFα, IL-1β, IL-6, and IL-18 in LPS-stimulated human macrophages [37, 276, 294]. But 
the theoretically presumed link between parasympathetic neurons and immune cells 
found no anatomic correlate as it currently accepted, that all primary and secondary 
immune organs, including the spleen, receive innervation only by sympathetic 
postganglionic neurons and no cholinergic vagal input [189]. More recent studies 
employing methods with increased sensitivity such as anterograde labelling also failed to 
detect a direct interaction between vagal nerve endings and macrophages in the gut or 
spleen [84, 166]. 
A non-neuronal origin of the splenic ACh isolated by Dale had not been taken into 
consideration for a long time. But later, ACh was identified in blood [127, 132], in the 
proximity of lymphocytes [133], that were soon after described to possess all essential 
components for a non-neural cholinergic system, including its synthetizing enzyme 
choline acetyltransferase (ChAT) [79, 235]. ChAT-producing T cells are currently thought 
responsible for Tracey’s described anti-inflammatory cholinergic reflex. Rosas-Ballina et 
al. brought evidence that vagal stimulation triggers release of norepinephrine from 
sympathetic neurons of the splenic nerve, inducing ACh secretion through activation of 
β-adrenoceptors on T cells [241]. The released ACh acts on the nAChRs of splenic 
CHAPTER 1                                                                                          INTRODUCTION 
 17 
macrophages, dampening cytokine production via the Janus kinase (Jak)2- signal 
transducer and activator of transcription  (STAT3) signaling pathway [241].  
From the various nAChR subunits identified on the surface of immune cells, α7 received 
the most attention, due to the immunemodulatory properties it was attributed with as part 
of the inflammatory reflex described by Tracey. Pro-inflammatory cytokine levels in 
endotoxemic α7 knockout mice significantly exceeded those of wild-type controls and 
were not influenced by cholinergic agonists [276, 294]. Further studies provided evidence 
of the dual inonotropic/metabotropic nature of α7 nAChRs, that elicit downstream effects 
by either transiently increasing intracellular Ca2+ or by engaging more prolonged 
signaling events [124, 139, 227]. 
Adding to the further characterization of immune cell nAChRs, our group suggested a 
cholinergic mechanism that potently inhibits ATP-mediated inflammasome activation 
and therefore IL-1β maturation in human and rat monocytes via the α7, α9, and α10 
nAChR subunits [106, 233, 311]. Monocyte-lineage cells, as main IL-1β producers are also 
capable of producing ACh, depending on their tissue distribution and immunological 
status [141, 245, 299]. A marginal ChAT mRNA expression was detected in splenic, lung 
and alveolar macrophages and monocytes as well as in mature and immature DCs during 
resting conditions [107, 141, 301]. In contrast, peritoneal macrophages have no ChAT 
activity, neither at rest nor when activated [134]. Kawashima showed that LPS and other 
TLR agonists induce ACh synthesis in DCs and macrophages [134], whereas our group 
pointed out, that activated monocytes accumulating in blood vessels of rat renal grafts 
produce ACh during acute rejection [107, 301]. As monocytic cells express all five M1–M5 
muscarinic AChR (mAChR) subtypes and various nAChR subunits, an autocrine 
modulation of pro-inflammatory cytokine release during immune challenge was 
suggested. Hecker et al. further provided evidence that certain pathogens, by producing 
phosphocholine (PC)-modified macromolecules can exploit this nicotinergic anti-
inflammatory mechanism to evade the immune system of the host [106]. Backhaus et al. 
showed that the anti-inflammatory properties dipalmitoylphosphatidylcholine (DPPC), as 
the main lipid constituent of surfactant, are at least partially accounted for by a similar 
cholinergic mechanism [19].  
All these findings extend the significance of the non-neural cholinergic system beyond 
the frame of a neuronal-immune reflex involving the vagus nerve and splenic immune 
cells. This prompted us to suggest that this cholinergic control mechanism might be 
involved in other key immunomodulatory events working to contain inflammation to a 
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local event and to properly compartmentalize the immune response. As leukocyte 
trafficking, inherently standing under the influence of chemokines, is central to many of 
these immune events, our present study is aimed at investigating the cholinergically 
mediated immunomodulatory properties of chemokines. 
1.5 Aim of the study 
Chemokines and ATP are among the first mediators released at inflammatory sites that 
can enter the circulation via damaged blood vessels. When encountering ATP, circulating 
primed monocytes receive their signal for inflammasome activation, but releasing IL-1β 
into the blood stream before having reached the site of injury would imply an inefficient 
immune response with enhanced systemic inflammation in the detriment of a reduced 
local immune cell infiltration.  
Therefore, we predict a prioritization of the chemotactic signal that enables monocytic 
infiltration of the injured tissue but prevents premature release of IL-1β  into the blood 
stream, thus avoiding SIRS. This prediction prompted us to investigate, whether 
chemokines can engage the already described non-neuronal cholinergic control 
mechanism to inhibit the ATP-dependent release of IL-1β by LPS-primed human 
monocytic cells. 
In the current study we test whether the monocyte attracting chemokines CCL3, CCL4 
and CCL5 inhibit the release of IL-1β by human monocytes, by conducting in vitro 
experiments using the monocytic U937 cell line as well as freshly isolated peripheral 
blood mononuclear cells (PBMCs). Furthermore, we aim to describe the molecular 
mechanism initiated down-stream of the chemokine/receptor interaction and ending with 
an inhibition of IL-1β release. 
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2 Material and Methods 
2.1 Material 
2.1.1 Cell line 
U937 (German Collection of Microorganisms and Cell Culture, Braunschweig, 
Germany) 
2.1.2 Chemicals and reagents 
[V11L; V16D]ArIB, kindly provided by J. Michael McIntosh from the Department of 
Biology, University of Utah, Salt Lake City, UT, USA 
2′(3′)-O-(4-benzoyl-benzoyl)adenosin 5′-triphosphat-triethylammonium salt (BzATP) 
(Sigma-Aldrich, Taufkirchen, Germany or Jena Bioscience, Jena, Germany ) 
2-Mercaptoethanol (Roth, Karlsruhe, Deutschland) 
α-bungarotoxin (Tocris Bioscience, Bristol, UK) 
Acetic acid, 96% p.a. (pro analysi) (Riedel-deHaën, Hannover, Germany) 
Acetylcholine (ACh) (Sigma-Aldrich) 
Acrylamide 30% solution, Rotiphorese® Gel 30 (Roth) 
Agarose (Invitrogen™, Life Technologies, Darmstadt, Germany) 
Ammonium persulfate (APS) (Roth) 
Apyrase (Sigma-Aldrich) 
Aqua destillata (dH2O) (B. Braun, Melsungen, Germany) 
Arachidonyl trifluoromethyl ketone (ATK) (Enzo Life Sciences, Lausen, Switzerland) 
Bovine serum albumin (BSA), ≥96% p.a. (Sigma-Aldrich)  
Bromoenol lactone (BEL) (Enzo Life Sciences) 
Bromophenol blue (Roth) 
CCL3L1 (MIP-1α), human recombinant (R&D Systems, Wiesbaden, Germany) 
CCL4 (MIP-1β), human recombinant (R&D Systems) 
CCL5, human recombinant (R&D Systems) 
CCR1 human siRNA (siRNA) ON-TARGETplus SMARTpool (GE Dharmacon, 
Lafayette, CO, USA)  
CCR3 human siRNA ON-TARGETplus SMARTpool (GE Dharmacon)  
CCR5 human siRNA ON-TARGETplus SMARTpool (GE Dharmacon)  
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CXCL12, human recombinant (R&D Systems) 
CXCL16, human recombinant (R&D Systems) 
Demineralized water (University Hospital Gießen, Germany) 
DNA Gel Loading Dye 6X (Thermo Scientific™, Life Technologies) 
DPBS, Dulbecco’s phosphate buffered saline (PBS) without calcium chloride (CaCl2) 
and magnesium chloride (MgCl2) (Gibco®, Life Technologies) 
Ethylenediaminetetraacetic acid (EDTA) (Serva, Heidelberg, Germany) 
Fetal calf serum (FCS) (Biochrome, Berlin, Germany)  
GelRed™ Nucleic Acid Gel Stain (Biotium, Hayward, CA, USA) 
GeneRuler 100 bp Plus DNA ladder (Thermo Scientific™, Life Technologies) 
GlutaMAX™ (Gibco®, Life Technologies) 
Glycerol, ≥99% p.a. (Sigma-Aldrich) 
Glycine, Pufferan® ≥99% p.a. (Roth) 
Heparin-Natrium, 25000 I.U./5 ml (Merckle, Blaubeuren, Germany) 
Hydrochloric acid (HCl), 1 N Titripur® Reag (Merck, Darmstadt, Germany) 
Lipopolysaccharide (LPS), Escherichia coli, ≥95% p.a., L2654 (Sigma-Aldrich)  
M-MLV reverse transcriptase (RT) ribunoclease (RNase) H(-) Point Mutant (Promega, 
Mannheim, Germany) 
M-MLV-RT reaction buffer 5x (Promega) 
Magnesium chloride (MgCl2), 25 mM (Promega) 
Mecamylamine hydrochloride (Sigma-Aldrich) 
Methanol, high pressure liquid chromatography (HPLC) grade, ≥99.9% (Sigma-
Aldrich) 
Mucocit® T (Schülke, Norderstedt, Germany) 
Nigericin (Sigma-Aldrich) 
ON-TARGETplus Nontargeting Control Pool (GE Dharmacon)  
Polymerase chain reaction (PCR) Nucleotide Mix (dNTPs), cGMP-Grade (Promega) 
PLA2G6 human siRNA ON-TARGETplus SMARTpool (GE Dharmacon)  
Platinum® SYBR® Green qPCR SuperMixUDG (Invitrogen™, Life Technologies) 
Potassium chloride (KCl), p.a. (Merck) 
Potassium dihydrogen phosphate (KH2PO4), p.a. (Merck) 
Powdered milk, blotting grade (Roth) 
Precision Plus Protein™ Standards, Dual Color (Bio-Rad, München, Germany) 
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Protease inhibitor cocktail tablets, Complete® Mini (Roche Diagnostics, Mannheim, 
Germany) 
Random primers (Promega) 
RgIA4, kindly provided by J. Michael McIntosh from the Department of Biology, 
University of Utah, Salt Lake City, UT, USA 
RNase-free water (Quiagen, Hilden, Germany) 
RNasin® RNase inhibitor (Promega) 
Sodium chloride (NaCl), ≥99%, p.a. (Sigma-Aldrich) 
Sodium dodecylsulfate (SDS), ≥99.9% ultrapure (Roth) 
Sodium hydroxide (NaOH) 1N Titripur® Reag (Merck)  
Sodium dihydrogen phosphate (NaH2PO4), p.a (Merck) 
Strychnine hydrochloride (Sigma-Aldrich)  
Tetramethylethylenediamine (TEMED) (Roth, Karlsruhe, Germany) 
Tris Pufferan®, ≥99.9% p.a. (Roth, Karlsruhe, Germany) 
Trypan blue solution, 0.4% for microscopy (Sigma-Aldrich) 
Türk’s solution (Merck) 
Tween® 20 (Merck) 
X-ray developer concentrate, X-Ray (Adefo-Chemie, Dietzenbach, Germany) 
X-ray fixer concentrate, X-Ray (Adefo-Chemie) 
2.1.3  Antibodies 
Table 1: Primary and secondary antibodies used for western blotting: characteristics and suppliers. 
iPLA2β, calcium-independent phospholipase A2β; Ig, immunoglobulin; HRP, horseradish peroxidase. 
 
 
Antibody Type Host 
species 
Clonality Supplier Product 
number 
anti- iPLA2β primary rabbit polyclonal Sigma-Aldrich SAB4200129 
anti-β-actin primary mouse monoclonal Sigma-Aldrich A1978 
anti-rabbit Ig, 
HRP labeled 
secondary goat polyclonal Dako, Glostrup, 
Denmark 
P0448 
anti-mouse Ig, 
HRP labeled 
secondary rabbit polyclonal Dako P0161 
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2.1.4 Consumables and expendables 
Amicon® Ultra Centrifugal filters, 3 kDa cut-off (Merck) 
Conical tubes BD Falcon™ 10/50 ml (Greiner bio-one, Frickenhausen, Germany) 
Culture flask T75 160 ml (Sarstedt, Nümbrecht, Germany) 
Electrophoresis chambers (Keutz Labortechnik, Reiskirchen, Germany) 
Glass Pipettes 10/20 ml (Greiner bio-one) 
High-performance chemiluminescence films (GE Healthcare Bio-Sciences, Uppsala, 
Sweden) 
Leucosep™ 227 288 (Greiner bio-one) 
Multiwell plates 12-/24-/96-wells (Greiner bio-one) 
Neubauer cell-counting chamber 0.0025 mm² (LO-LaborOptik, Lancing, England)  
Nitrile gloves Vasco® (B. Braun) 
PCR plate, 96-well (Thermo Scientific™, Life Technologies) 
Pipette filter tips np Nerbe-Plus 100/1250 µl (Novolab NV, Geraardsbergen, Belgium) 
Pipette tips 10/200/1000 µl (Sarstadt, Nümbrecht, Germany) 
Polyvinylidene difluoride (PVDF)-membrane Immobilon®- pore size: 0.45 µm (Merck) 
Reaction tubes Safe Seal 0.5/1.5/2 ml (Sarstedt) 
Sterile syringe 20 ml (B. Braun) 
X-Ray cassette (Dr. Goos-Suprema GmbH, Heidelberg, Germany) 
2.1.5 Instruments 
Analogue tube roller SRT9 (Stuart, Staffordshire, UK) 
Balance WL100826 (Kern & Sohn, Balingen, Germany) 
Block heater S81B25034 (Peqlab Biotechnologie, Erlangen, Germany) 
Centrifuges Rotina 420R, Mikro 220 and Mikro 200 R (Hettich, Tuttlingen, Germany) 
Digital camera Olympus C4000-Zoom (Olympus, Hamburg, Germany) 
Electrophoresis power supply Consort EV231/E835 (Von Keutz Labortechnik) 
Epoch spektrophotometer (BioTek, Bad Friedrichshall, Deutschland) 
FLUOstar OPTIMA spectophotometer (BMG Labtech, Offenburg, Germany) 
Gel imaging system (Intas, Göttingen, Germany) 
Incubator Heracell™ 240i (Thermo Scientific™, Life Technologies) 
Laminar flow hood (Integra Biosciences GmbH, Konstanz, Germany)  
Magnetic stirrer RH basic 2 (IKA®, Staufen, Germany) 
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Microscopes Labovert and Laborlux (Leitz, Wetzlar, Germany) 
Mini Plate Spinner MPS 1000 (Labnet, Edison, USA) 
Mini Spin centrifuge (Abimed, Langenfeld, Germany) 
NanoDrop 1000 (Peqlab Biotechnologie) 
Nucleofector® Device (Lonza Group Ltd., Basel, Switzerland) 
PH-Meter UB-10 (Denver Instrument, Göttingen, Germany) 
Pipettes Reference 100-1000; 10-100; 0.5-10 µl Pipetus® (Eppendorf, Hamburg, 
Germany)  
Pipetus® (Hirschmann®, Eberstadt, Germany) 
Step-One Real-time PCR-System (Applied Biosystems®, Life Technologies) 
Rocking shaker ST5 (Kobe, Marburg, Germany) 
Thermal Cycler G-Storm, GS482 (AlphaMetrix Biotech, Rödermark, Deutschland)  
Tissue homogenizer MM301 (Retsch, Haan, Germany) 
Transilluminator (Biozym Scientific, Oldendorf, Germany) 
Ultrasonic bath Sonorex Super RK102H (Bandelin, Berlin, Germany)  
Vortex Mixer Reax2000 (Heidolph, Schwabach, Germany) 
Water bath (Köttermann Labortechnik, Uetze/Hänigsen, Germany) 
2.1.6 Buffers and solutions 
Buffer/ Solution Source/ Recipe  
APS solution 200 mg APS were dissolved in 400 ml 
demineralized water shortly before usage 
PBS, 10x 1.37 M NaCl 
27 mM KCl 
80 mM NaH2PO4 
15 mM KH2PO4 
The pH of the resulting solution was 
adjusted to 7.2. 
PBS, 1x 
 
was obtained by a 1:10 dilution of PBS 
(10x) with dH2O. The pH was maintained 
at 7.2. 
PBS-T (Tween 0.1 %) 0.1% (v/v) was mixed into the PBS (1x) 
solution. 
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Resolving gel buffer 18.16 g Tris Pufferan® (1.5 M) were 
dissolved in 70 ml demineralized water 
and titrated with 1 N HCl until a pH of 8.8. 
4 ml of the 10% SDS solution and dH2O 
up to a volume of 100 ml were added. 
RPMI 1640 cell culture medium Gibco® by Life Technologies, Darmstadt, 
Germany 
Sample buffer 1 62.5 mM Tris-HCl, pH 6.8 
2.3% (w/v) SDS 
1 protease inhibitor cocktail tablet per 20 
ml 
Sample buffer 2 62.5 mM Tris-HCl, pH 6.8 
40% (v/v) glycerol 
2.3% (w/v) SDS 
16% (v/v) 2-mercaptoethanol 
0.025% (w/v) bromphenol blue 
1 protease inhibitor cocktail tablet per 10 
ml 
SDS stock solution (10 %)  
10 g SDS were dissolved in 100 ml 
demineralized water.  
Stacking gel buffer 
0.5 M Tris-HCl, pH 6.8  
0.4% (w/v) SDS  
Transfer buffer 
20 mM Tris  
200 mM glycine (200 mM) 
0.05 (w/v) SDS 
20% (v/v) methanol 
TAE, 50x 
 
2 M Tris  
0.06 M EDTA  
5.71% (v/v) acetic acid  
if necessary, the the solution was adjusted 
by titration with either 1 N NaOH or 1 N 
HCl to a pH of 8. 
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TAE, 1x 
was obtained by a 1:50 dilution of TAE 
(50x) with dH2O. 
Tris-HCl buffer, 1 M (pH 6.8) obtained by dissolving 121.14 g Tris 
Pufferan® in 1 litre demineralized water 
and titrating with 1 N HCl until a pH of 
6.8. 
Table 2: Buffers and solutions. APS, ammonium persulfate; PBS, phosphate buffered saline; NaCl, sodium 
chloride; KCl, potassium chloride; NaH2PO4, sodium dihydrogen phosphate; KH2PO4, potassium 
dihydrogen phosphate; dH2O, aqua destillata; PBS-T, phosphate buffered saline with Tween; HCl, 
hydrochloric acid; SDS, sodium dodecylsulfate; EDTA, ethylenediaminetetraacetic acid; TAE, tris-acetate 
EDTA; NaOH, sodium hydroxide; w/v, weight per volume; v/v, volume per volume.  
2.1.7 Kits 
Amaxa® Cell Line Nucleofactor® Kit C (Lonza Group Ltd.) 
CytoTox 96® Non-Radioactive Cytotoxicity Assay (Promega) 
Lumi Light Western Blotting Substrate (Roche Diagnostics, Mannheim, Germany) 
Micro BCA Protein Assay Kit (Thermo Scientific™, Life Technologies) 
Min Elute® PCR Purification Kit (Qiagen) 
Qiagen RNeasy Miniprep Kit (Qiagen)  
Quantikine® ELISA Human IL-β/IL-1F2 (R&D Systems) 
Silver Stain Plus (Bio-Rad Laboratories, Munich, Germany)  
2.2 Methods 
2.2.1 Cell culture experiments 
2.2.1.1 Culture methods and cell counting 
Cell culture experiments have been carried out on the U937 human histiocytic lymphoma 
cell line. The cells were cultured in RPMI 1640 cell culture medium supplemented with 
10% fetal calf serum (FCS), and 2 mM GlutaMAX™, at 37 °C and in humidified 
atmosphere with 5% CO2. Change of the supplemented cell culture medium and 
passaging of the cells took place twice a week. All experiments have been carried out 
using sterile reagents and consumable materials under a laminar flow hood. 
At the beginning of each experiment, haemocytometric counting was performed. For this, 
the cell suspension from a culture flask was centrifuged for 8 min at room temperature 
and 500 g. The supernatant was discarded and the cell pellet resuspended in 10 ml fresh 
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supplemented culture medium. 10 µl of the fresh cell suspension were stained with 90 µl 
0.2% trypan blue solution and loaded onto a Neubauer cell-counting chamber. Viable 
cells were counted under the microscope, then, according to the calculated cell 
concentration, the cell suspension was set to a density of 106 cells/ml. 
2.2.1.2 Experimental outline 
The experimental workflow comprised the main steps depicted in Figure 1, namely cell 
priming with 1 µg/ml LPS from Escherichia coli for 5 h, followed by stimulation with 
100 µM BzATP (2´(3´)-O-(4-benzoyl-benzoyl)ATP trieethylammonium salt), a specific 
ligand of ATP receptor P2X7. Chemokines, nicotinic antagonists or inhibitors of 
phospholipases A2 (PLA2s) were added to the cell suspension simultaneously with 
BzATP. After another 30 min of incubation, supernatants were separated by 
centrifugation for 8 min, at 500 g and room temperature and used for IL-1b quantification 
using an enzyme-linked immunosorbent assay (ELISA). Lactate dehydrogenase (LDH) 
concentrations as a measure of cell death were also determined from the supernatants 
using the CytoTox 96® colorimetric assay kit. 
 
Figure 1: Interleukin-1b (IL-1b) release experiments on U937 cells. U937 cells were primed with 
lipopolysaccharide (LPS) for 5 h, after which chemokines in the presence or absence of nicotinic 
acetylcholine receptor (nAChR) antagonists or phospholipase A2 (PLA2) inhibitors were added, together 
with 2´(3´)-O-(4-benzoyl-benzoyl)ATP trieethylammonium salt (BzATP). Following another 30 min of 
incubation, supernatants were separated and used for interleukin-1b (IL-1b) and lactate dehydrogenase 
(LDH) measurement. 
 
Each experiment included a set of control samples listed in Table 3.  
To determine the total release of LDH, a sample consisting of 106 untreated cells was 
stored at -80 °C and thawed to ensure lysis of all contained cells with consequent 
maximum LDH release.  
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Control experiments U937 cells Ligands 
1. 106 cells/ml -  
2. 106 cells/ml LPS 
3. 106 cells/ml LPS, BzATP 
4. total release of LDH  106 cells/ml -  
5. medium -  -  
Table 3: List of control experiments. Each experiment included a set of 3 controls as follows: 1. untreated 
cells, 2. lipopolysaccharide (LPS)-primed cells, 3. cells primed for 5 h with LPS and activated with 2´(3´)-
O-(4-benzoyl-benzoyl)ATP trieethylammonium salt (BzATP, 100 µM, 30 min). For generating reference 
values in the subsequent assays for interleukin-1b (IL-1b) and lactate dehydrogenase (LDH) measurement, 
a total release of LDH sample consisting of untreated cells that were lysed at -80 °C (4) and a cell culture 
medium sample (5) were also included. 
2.2.1.3 Dose-response experiments, nAChR antagonization and PLA2 inhibition 
The experiments were carried out in 24-well plates. In a first step, 1 ml cell suspension 
containing 106 cells was loaded per well and 1 µl of previously sonicated LPS stock 
solution (1 µg/µl) was added per well. The cells were then incubated, as previously 
described, for 5 h at 37 °C and in humidified atmosphere with 5% CO2. Chemokines 
CCL3, CCL4, CCL5, CXCL12, CXCL16 were delivered in lyophilized form and 
dissolved in 100 µl PBS with 0.1% bovine serum albumin (BSA) resulting in a stock 
solution with a concentration of 50 ng chemokine/µl, that was then divided in 10 µl 
aliquots. The chemokine solutions were stored at -20 °C, thawed and sonicated before 
usage. For the dose-response experiments LPS-primed U937 cells were treated with 
increasing concentrations (0.1, 0.5, 1, 5, 10 and 50 ng/ml) of each of the chemokines 
tested.  
In a second set of experiments, the LPS-primed cells were sequentially treated with the 
following nAChR antagonists: 100 µM mecamylamine hydrochloride (Mec), 1 µM α-
bungarotoxin (α-Bun), 10 µM strychnine (Stry) or the conotoxin-derived peptides 
[V11L; V16D]ArIB (500 nM) or RgIA4 (200 nM) [112, 233, 240, 300]. The effective 
concentrations of CCL3, CCL4 or CCL5 were subsequently added, followed by 
activation with 100 µM BzATP. To inhibit phospholipase A2 (PLA2), 50 µM arachidonyl 
trifluoromethyl ketone (ATK) or 50 µM bromoenol lactone (BEL) was applied prior to 
CCL3 and BzATP addition in a further experimental series. The cells were incubated with 
the applied reagents for another 30 min under standard conditions, then supernatants were 
harvested and stored at -20 °C until further processing. Each experiment was repeated 
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four to five times. 
2.2.1.4 Experiments using nigericin 
LPS-primed U937 cells were treated with apyrase (0.5 U/ml), an enzyme that cleaves 
ATP, in the presence or absence of the efficient inhibitory doses of chemokines CCL3, 
CCL4 and CCL5. Simultaneously, the pore-forming bacterial toxin nigericin (50 µM) was 
added and the cells were incubated for 30 min under standard conditions. The cell 
suspensions were centrifuged, supernatants collected and stored until further processing. 
Two additional samples of nigericin-treated cells and a medium sample with added 
nigericin were included to be used as control samples in the CytoTox 96® colorimetric 
assay for LDH measurement.  
2.2.1.5 Gene silencing  
In order to knock-down the expression of the chemokine receptor and iPLA2b genes, 
U937 cells were transfected with small interfering RNA (siRNA) ON-TARGETplus 
SMARTpool targeting human CCR1 or PlA2G6 using the AmaxaÒ Cell Line 
NucleofectorÒ Kit C. ON-TARGETplus Non-targeting Control Pool was used as a 
negative control. The lyophilized siRNA was resuspended in 250 µl RNAse-free water in 
order to obtain a 20 µM stock solution that was aliquoted into 5 µl portions. The siRNA 
aliquots were stored at -80 °C and thawed before usage. 
An appropriate number of wells on a 12-well plate were filled with 1 ml supplemented 
culture medium (RPMI 1640 with 10% FCS and 2 mM GlutaMAX™ solution) and 
equilibrated in the humidified 37 °C/5% CO2 incubator. The required number of cells 
(106 cells per sample) was centrifuged at 110 g for 10 min at room temperature. After 
discarding the supernatant, each cell pellet was resuspended in 100 µl NucleofectorÒ 
Solution per sample. This cell suspension was mixed with 2 µl siRNA stock solution 
targeting human CCR1, PlA2G6 or with control siRNA, respectively. The cell/siRNA 
suspension was transferred into the certified cuvette and electroporation was performed 
using the appropriate programme of the NucleofectorÒ device. 500 µl of pre-equilibrated 
culture medium were added to each cuvette and each sample was transferred into the 
prepared 12-well plate. The cells were incubated under standard conditions for 48 h 
before further processing. 
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After incubation, the transfected cells were used in IL-1β release experiments according 
to the protocol outlined in section 2.2.1.2., which involves priming with LPS followed by 
addition of effective chemokine (CCL3, CCL4 and CCL5) concentrations and BzATP. 
Centrifugation (8 min, 500 g, room temperature) was performed after further 30 min of 
incubation and supernatants were collected for IL-1β and LDH measurement, whereas 
the cells were washed in DBPS and centrifuged in order to obtain cell pellets that were 
stored at -20 °C for future mRNA and protein extraction.  
2.2.1.6 Conditioned medium  
The required number of cells was centrifuged (8 min, room temperature, 500 g), the 
supernatant discarded and the cells resuspended in FCS-free medium. Cells were then 
primed with LPS as previously described, then 10 ng/ml CCL3 were added followed by 
30 min of incubation. 2 ml fractions of the supernatant separated by centrifugation (8 min, 
500 g, 4 °C) were loaded on to Amicon® Ultra Centrifugal filters with a cut-off of 3 kDa. 
A control ultrafiltrate was produced by adding the chemokine to the supernatant of 
LPS-primed U937 cells just shortly before ultrafiltration.  
Ultrafiltration was performed at 4000 g for 20 min at 4 °C. The collected flow-through 
from the Amicon® filters was used in IL-1β release experiments, on LPS-primed cells 
with or without addition of RgIA4 or [V11L; V16D]ArIB. The efficiency of the 
ultrafiltration was controlled by SDS-gel electrophoresis followed by silver staining. For 
this purpose, 40 µl of each of the three fractions, namely the supernatant before 
ultracentrifugation, the ultrafiltrate (UF) and the high molecular mass fraction (HF) 
obtained after ultrafiltration were mixed with 10 µl sample buffer 2 and stored at -20 °C 
until further use. 
2.2.2 Experiments on human PBMCs 
Studies on human blood from male healthy non-smoking volunteers were approved by 
the local ethics committee of the University of Giessen (No. 81/13). For PBMC isolation, 
10 ml of blood was drawn from a peripheral vein into a sterile syringe containing 175 I.U. 
Heparin. Following a dilution with PBS with 0.1% BSA up to a total volume of 25 ml, 
the blood was transferred into Leocosep™ gradient tubes. Through centrifugation 
(20 min, 800 g and room temperature), the enriched cell fraction containing the PBMCs 
covered by a plasma layer was separated above the porous barrier of the gradient tube. 
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The plasma was discarded and the PBMCs collected and suspended in 5 ml supplemented 
culture medium (RPMI 1640 with 10% FCS and 2 mM GlutaMAX™). The cells were 
counted following the same method described in section 2.2.1.1., except for using Türk’s 
solution for cell staining. The cell suspension was accordingly diluted to obtain a cell 
density of 106 cells/ml cell suspension. Cell pellets for subsequent RNA extraction and 
real-time reverse transcription polymerase chain reaction (RT-PCR) experiments were 
obtained by centrifugation after washing with DPBS.  
 
Figure 2: Interleukin-1b (IL-1b) release experiments on primary human cells. Human peripheral blood 
mononuclear cells (PBMCs) were freshly separated from lipopolysaccharide (LPS)-primed human blood 
by Leucosep™ gradients. After 3 h of incubation, 2´(3´)-O-(4-benzoyl-benzoyl)ATP trieethylammonium 
salt (BzATP, 100 µM) was added to adherent cells in fresh culture medium for 30 min in the presence or 
absence of CCL3 (10 ng/ml). IL-1β and lactate dehydrogenase (LDH) were measured in cell culture 
supernatants. 
In IL-1β release experiments, as depicted in Figure 2, 10 ml of heparinized blood were 
pulsed with 0.5 ng LPS/ml, then subjected to density gradient centrifugation as described 
above. The separated PBMCs were seeded on multi-well plates at a density of 106 cells 
per well and cultured for 3 h under standard conditions. Non-adherent cells were removed 
together with the culture medium, while fresh culture medium was added to the adherent 
cells that were then treated with BzATP (100 µM) in the presence or absence of CCL3 
(10 ng/ml). After further 30 min of incubation, supernatants were collected for IL-1β and 
LDH measurement.  
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2.2.3 Measuring IL-1β concentration using ELISA 
The IL-1β levels from the samples obtained in the cell culture experiments were 
determined using the Quantikine® ELISA Human IL-β immunoassay kit, which implies 
a solid phase quantitative sandwich enzyme technique. The assay was performed 
following the manufacturer’s instructions. IL-1β present in the samples was bound by a 
monoclonal antibody specific to human IL-1β, immobilized on the surface of the provided 
96-well microplate. A second, enzyme-linked polyclonal antibody specific to human 
IL-1β was added, whose reaction with the appropriate substrate resulted in color 
development proportional to the amount of IL-1β in the samples. The absorption was 
measured using the FLUOStar OPTIMA spectrophotometer at a wavelength of 450 nm. 
According to the data sheet, the analytical sensitivity of the assay is of 1 pg/ml with a 
detection range for cell culture supernatatns of 3.9 - 250 pg/ml. 
2.2.4 Estimation of cell death by LDH measurement 
Cell viability in the samples was determined by measuring the amount of the cytosolic 
LDH released to the sample supernatants by using the CytoTox 96® Non-Radioactive 
Cytotoxicity Assay, according to the manufacturer’s instructions.  This colorimetric assay 
is based on the enzymatic formation of a red formazan product, in a manner proportional 
to the amount of active LDH. The amount of colour formed was determined 
by spectrophotometric absorbance at 490 nm. Cell viability was measured by calculating 
the ratio of the released LDH in each sample to the total LDH released by lysis of 106 
cells.  
2.2.5 mRNA quantification  
Real-time RT-PCR was employed to analyze mRNA expression of the chemokine 
receptors in U937 cells. The target receptors for the studied chemokines are listed in Table 
4.  
Gene silencing efficiency in the transfection experiments was also evaluated through 
real-time RT-PCR. 
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Chemokine Receptors 
CCL3 CCR1, CCR5 
CCL4 CCR1, CCR5 
CCL5 CCR1, CCR3, CCR5 
CXCL12 CXCR4, ACKR3 (CXCR7) 
CXCL16 CXCR6 
Table 4: Target receptors for the studied chemokines, adapted and modified from C. Schütt [251]. 
2.2.5.1 RNA isolation 
RNA was isolated from untreated PBMCs and U937 cells as well as from siRNA-treated 
U937 cells using Qiagen RNeasy Miniprep Kit, a spin column based RNA purification 
method, following the instructions provided by the manufacturer. The concentration of 
the extracted RNA was measured spectophotometrically using Nano Drop 1000 at the 
wavelength of 260 nm. The samples were then stored at -80 °C until further usage. 
2.2.5.2 Complementary DNA (cDNA) synthesis 
Reverse transcription was performed to obtain cDNA transcripts from the extracted RNA 
using a two-step protocol. Firstly, 1 µg of purified RNA was mixed with 1 µg random 
primers then with dH2O up to a volume of 10 µl. The samples were heated at a 
temperature of 70 °C for 5 min, then cooled down to 4 °C for 5 min using the Thermal 
Cycler G-Storm from AlphaMetrix Biotech. This step is intended to melt the secondary 
structure of the template. The samples were then immediately placed on ice and shortly 
vortexed. In a second step the components listed in Table 5 were mixed and then added 
to the pre-incubated 10 µl RNA samples, thus obtaining a final sample volume of 25 µl. 
The newly obtained samples were shortly vortexed then incubated in the Thermal Cycler 
G-Storm at 25 °C for 10 min, then at 42 °C for 1 h followed by 15 min at 70 °C for cDNA 
synthesis. The obtained cDNA was ready for direct use or could be stored at -20 °C. 
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Component Amount (µl) 
M-MLV-RT reaction buffer 5x 5 
PCR nucleotide mix (dNTPs) 1.5 
Recombinant RNasin® Ribonuclease Inhibitor 0.5 
M-MLV RT RNase H(-) Point Mutant  0.5 
dH2O  7.5 
Table 5: Components of the master mix used for complementary deoxyribonucleic acid (cDNA) synthesis. 
RT, reverse transcriptase; PCR, polymerase chain reaction; dNTP, deoxynucleotide triphosphate; RNase, 
ribonuclease, dH2O, aqua destillata. 
2.2.5.3 Real-time PCR 
For each of the analyzed genes, the components for the real-time PCR were combined in 
a master mix using the formula and reagents listed in Table 6. The Platinum®SYBR® 
Green qPCR SuperMixUDG contains, according to the manufacturer, 
deoxyribonucleotide triphosphates (dNTPs), the recombinant Taq DNA polymerase and 
SYBR® Green I Dye.  
Component Amount (µl) 
Platinum®SYBR® Green qPCR SuperMixUDG 13 
dH2O 8 
50 mM MgCl2  1 
1 µM forward primer  0.5 
1 µM reverse primer  0.5 
Table 6: Components of the master mix used for real-time polymerase chain reaction (PCR). dH2O, aqua 
destillata, MgCl2, magnesium chloride. 
All primers were synthetized by Eurofins Genomics (Ebersberg, Germany) and were 
delivered in lyophilized form. The employed primer sequences are indicated in Table 7.  
2 µl cDNA were added to the master mix, resulting in a total sample volume of 25 µl that 
was loaded onto a 96-well plate. In negative controls the cDNA was replaced by dH2O. 
cDNA from freshly isolated human PBMCs was included as a positive control. For the 
real-time PCR, evaluating the efficiency of gene silencing, cDNA from non-transfected 
cells was included. The plate was shortly centrifuged, then using Applied Biosystems 
Step-One the real-time PCR was initialized by heating the samples to 50 °C for 2 min 
then at 95 °C for 5 min followed by 45 amplification cycles, based on 3 steps: 
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• denaturation for 5 s at  95 °C;  
• primer annealing for 5 s at 60 °C; 
• elongation for 30 s at 72 °C. 
Hydroxymethylbilane synthase (HMBS), alias porphobilinogen deaminase (PBGD) was 
used as housekeeping gene for data normalization. Analysis of the relative gene 
expression between two samples was facilitated by the attached software (StepOne v2.3). 
The 2∆CT method was applied for calculation, using the threshold cycle (CT) values 
generated by the RT-PCR system, where ∆CT is the difference between the CT of the 
housekeeping gene and of the gene of interest.  The obtained mean value for the cells 
treated with control siRNA was set to one arbitrary unit.  
 
Gene Name  
Forward primer 5'-3'  Reverse primer 5'-3'  
Amplicon  
(Accession number) size (bp) 
CCR1 
GGA CAA AGT CCC TTG GAA CC GGA GTT GCA TCC CCA TAG TC 101 
(NM_001295.2) 
CCR3 
ATC CGG GCA AGA ACT TAT CG AGG ATG TGG TAC CAA AGG TCT C 114 
(NM_178328.1) 
CCR5 
CTG GCC AGA AGA GCT GAG AC GGG CTC CGA TGT ATA ATA ATT GA 116 
(NM_000579.3) 
CXCR4 
GGA GAA CCA GCG GTT ACC AT CAG GGT TCC TTC ATG GAG TC 100 
(NM_003467.2) 
CXCR6 
GGA ACA AAC TGG CAA AGC AT TGG CTG CTG TCA TTG AAA CT 107 
(NM_006564.1) 
ACKR3 (CXCR7) ACA GCA CAG CCA GGA AGG  AGT CGA AGA GAT GCA GAT CCA 107 
(NM_020311.2) 
PLA2G6 
CAT CCG TAA CCA CCC CAG C CGT TCT CCG CGC AAT TGG 109 
(NM_003560.2) 
HMBS 
GGC GCA GCT ACA GAG AAA GT AGC CAG GAT AAT GGC ACT GA 115 
(NM_001258209.1) 
Table 7: List of primers and their sequences used for real-time RT-PCR. CCR1, C-C motif chemokine 
receptor 1; CCR3, C-C motif chemokine receptor 3; CCR5, C-C motif chemokine receptor 5; CXCR4, C-
X-C motif chemokine receptor type 4; CXCR6, C-X-C motif chemokine receptor type 6; ACKR3 (CXCR7), 
atypical chemokine receptor 3 or C-X-C motif chemokine receptor type 7; PLA2G6, phospholipase A2 
group VI; HMBS, hydroxymethylbilane synthase; bp, base pairs. 
2.2.5.4 Agarose-gel electrophoresis 
To verify size and purity of the amplicons resulting from real-time PCR, these were 
separated by electrophoresis on a 1.5 % agarose gel. To prepare the gel, 1.2 g of agarose 
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were mixed with 80 ml Tris-acetate EDTA (TAE) 1x solution and heated for 3 min until 
the agarose was completely dissolved.  8 µl of GelRed™ Nucleic Acid Dye was added, 
the mixture was then cast into a tray and left to cool for 20 min. Afterwards, the gel was 
placed into the electrophoresis chamber filled with TAE 1x as a running buffer. 9 µl of 
each PCR product mixed with 2 µl of 6x DNA Gel Loading Dye were loaded into the gel 
pockets. 7 µl of a molecular mass marker (GeneRuler™ 100 bp DNA ladder) were loaded 
in the last gel pocket. The electrophoresis was performed for 30 to 40 min at 100 V. The 
DNA bands in the gel were viewed with an ultraviolet (UV) transilluminator, documented 
using the Olympus C4000-Zoom digital camera, processed and stored using 
AlphaDigiDoc 1201 software. 
2.2.5.5 PCR product purification and sequencing 
To further confirm the identity of the amplicons, DNA bands were excised from the gel 
and purified using MinElute® PCR Purification Kit from Qiagen, according the the 
manufacturer’s instructions. The PCR products were then sequenced by SeqLab 
(Göttingen, Germany).  
2.2.6 Protein biochemistry  
2.2.6.1 Determining protein concentration 
For protein extraction, each of the cell pellets collected from the transfection experiments 
were resuspended in 50 µl sample buffer 1, followed by a bead-beating homogenization 
process at 30 Hz for 5 min, heating at 95 ºC for 5 min and centrifugation (5 min, 5720 g, 
room temperature). The samples collected from the conditioned medium experiments 
(supernatant before ultracentrifugation, UF and HF) were thawed, heated and centrifuged 
under the same conditions. 10 µl from each of the resulting samples were taken to 
determine protein concentration by using the Micro BCA™ Protein Assay Kit. The assay 
involves a colorimetric reaction that is quantified by comparing absorbance at 562 nm to 
a set of standard BSA dilutions using spectrophotometry. 
Following the manufacturer’s instructions, a series of sample dilutions and BSA standard 
dilutions were incubated with the substrate, then the protein concentration was 
determined by absorbance measurement with the FluoStar OPTIMA spectrophotometer 
and data processing using the attached software. According to the determined protein 
concentrations, the samples were further diluted with a suitable amount of sample buffer 
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1 and sample buffer 2 (mixed in a 1:1 ratio) in order to obtain a final concentration of 
0.8 g/µl. 
2.2.6.2 SDS-gel electrophoresis 
Samples were separated on reducing SDS-polyacrylamide gels. The acrylamide 
concentration was chosen according to the molecular size of the protein of interest: a 15% 
SDS-gel for CCL3 detection, and a 10% SDS-gel for iPLA2β detection. 
The gels were prepared by mixing the substances in quantities listed in Table 8: 
 
Component 15% SDS-gel 10% SDS-gel 
dH2O 1050 µl 1830 µl 
resolving gel buffer 1076 µl 1080 µl 
Acrylamide, 30% solution 1100 µl 1460 µl 
APS solution 7.7 µl 7.7 µl 
TEMED 3 µl 3 µl 
Table 8: Components and their appropriate quantities used for preparing 15% and 10% SDS resolving 
gels.dH2O, aqua destillata; APS, ammonium persulfate; TEMED, tetramethylethylenediamine. 
 
After properly mixing the components, 3.75 ml of the resolving gel were poured into the 
gel assembly cassette, adding water on top of the resolving gel until the assembly cassette 
was filled. The gel was left to polymerize for about 40 min during which a stacking gel 
was prepared following the recipe depicted in Table 9. After removing the water, the 
stacking gel was poured onto the resolving gel so as to fill up the cassette, then a gel comb 
was introduced to form the gel pockets.   
 
Component Amount (µl) 
dH2O 1350 
stacking gel buffer 790 
acrylamide, 30% solution  312.5 
APS solution 5.62 
TEMED 4.5 
Table 9: Components and their appropriate quantities used for preparing the stacking gel. dH2O, aqua 
destillata; APS, ammonium persulfate; TEMED, tetramethylethylenediamine. 
 
After another 40 min, the gel comb was removed and the gel pockets washed with running 
buffer. The gel cassettes were assembled onto the electrophoresis apparatus that was filled 
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with running buffer. The gel pockets were each filled with 10 µl of the protein samples 
that were previously heated at 70 °C for 5 min and then centrifuged (5 min, 5720 g, room 
temperature). The dual colour Precision Plus Protein™ Standards Marker was added to 
one of the gel pockets. Electrophoresis was run at 80 V for 10 min in order to concentrate 
the samples in the stacking gel, then at 120 V for 75 min for protein separation according 
to their molecular mass. 
2.2.6.3 Silver staining 
The 15% SDS-gel slabs containing the separated proteins from the samples obtained in 
the conditioned medium experiments were stained with the Silver Stain Plus kit according 
to the manufacturer’s instructions and documented using a gel imaging system (Intas, 
Göttingen, Germany).  
2.2.6.4 Western blotting 
The proteins from the cells resulting from the transfection experiments, separated on 10% 
SDS-gels for iPLA2β detection were transferred onto Immobilon® polyvinylidene 
difluoride (PVDF) membranes. For this, each of the gel slabs was stacked onto a 
membrane, previously activated in methanol, between filter paper and sponges soaked 
with transfer buffer. The assembled stacks were then mounted onto the electrophoresis 
apparatus filled with transfer buffer. Protein transfer was performed over 90 min at 90 
mA. The membranes were then left to dry for 1 h, then activated for 1 min in methanol, 
rinsed with PBS, then blocked with 5% BSA diluted in PBS. The primary polyclonal 
rabbit antibodies directed to human iPLA2β were diluted 1:5000 in PBS and 2.5% 
powdered milk then incubated with the membranes overnight, at a temperature of 4 °C, 
under constant rotation. The next day, the membranes were washed 4 times for 7 min in 
PBS-T followed by 90 min of incubation with the secondary horseradish peroxidase-
labeled goat anti-rabbit Ig antibodies, diluted 1:5000 in PBS-T and 2.5% powdered milk. 
After three rinsing cycles with PBS-T and one with PBS, the membranes were incubated 
for 3 min with SuperSignal West Dura Extended Duration Substrate. Chemoluminescent 
detetection was used to visualize protein bands on film.  
To determine whether samples have been loaded equally across all wells, the membranes 
were rinsed three times with PBS, then incubated for 75 min with monoclonal mouse anti-
human β-actin antibodies (1:50000), as a loading control. After four further rinsing 
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cycles, bound primary antibodies were detected with secondary rabbit anti-mouse Ig 
horseradish peroxidase-labeled antibodies (1:5000) and the Lumi-Light substrate on High 
Performance Chemiluminescence Films. 
2.2.6.5 Densitometry 
To quantify Western blot signals, films were imaged using the AlphaEase software that 
measured the optical density (OD) of the immunepositive bands. iPLA2β expression was 
normalized by dividing the OD of iPLA2β protein bands to the OD of the β-actin loading 
control. The average of the determined values for cells treated with control siRNA was 
set to one arbitrary unit and the values for cells transfected with siRNA targeting PLA2G6 
were statistically compared to this unit for determining fold difference in protein 
expression.  
2.2.7 Statistical analyses 
Results are presented as individual data points, median and percentiles 25 and 75. Data 
were analyzed by non-parametric Kruskal-Wallis test followed by the Mann-Whitney 
rank sum test using the SPSS software (IBM SPSS statistics, version 23, Munich, 
Germany). Data obtained from primary leukocytes were analyzed by the Wilcoxon 
signed-rank test (SPSS software). p-values below 0.05 were considered as statistically 
significant. IC50 values were determined using GraphPad Prism® (Version 6, GaphPad 
Software) by fitting log-transformed concentration values and the original effect data. 
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3 Results 
3.1 CCL-induced inhibition of IL-1β release  
3.1.1 CCL chemokines dose-dependently inhibit IL-1β release 
First experiments were performed to determine whether CCL chemokines with an 
established role in monocyte chemotaxis influence IL-1β maturation and release by LPS-
primed and ATP-stimulated human monocytic U937 cells. U937 cells at a density of 106 
cells/ml were primed with LPS (1 µg/ml) for 5 h followed by activation with the P2X7R 
agonist BzATP (100 µM) for 30 min. Chemokines CCL3, CCL4 and CCL5 were added 
at increasing concentrations ranging from 0.1 to 50 ng/ml concomitantly with BzATP. 
IL-1β and LDH levels in the sample supernatants were determined using ELISA and a 
colorimetric assay, respectively. Basal IL-1β secretion, from the supernatants of untreated 
cells, was barely detectable. LPS priming alone did not increase IL-1β release into the 
cell culture medium when compared to basal levels. The consecutive application of LPS 
and BzATP, induced IL-1β secretion (median IL-1β concentration of 41 pg/ml, range 34 
– 57 pg/ml; n = 8) (Figure 3 a, c, e). In line with our hypothesis, the BzATP-induced 
release of IL-1β by LPS-primed human monocytic U937 cells was dose-dependently and 
efficiently inhibited by chemokines CCL3 (IC50 = 9.2 ng/ml), CCL4 (IC50 = 11.5 ng/ml) 
and CCL5 (IC50 = 51.3 ng/ml) (p = 0.029; n = 4, each). Notably, among the three tested 
CCL-chemokines, CCL3 was most potent in inhibiting IL-1β secretion, showing a 
significant inhibition from a concentration of 1 ng/ml (p = 0.029; n = 4) and reaching a 
full inhibitory effect at a concentration of 10 ng/ml (Figure 3 a). CCL4 and CCL5 were 
needed in higher concentrations of 5 ng/ml and 10 ng/ml respectively, to induce a 
significant inhibitory effect on IL-1β secretion, both chemokines reaching a fully 
inhibitory effect at a concentration of 50 ng/ml (Figure 3 c, e). When fully inhibitory 
concentrations of chemokines CCL3 (10 ng/ml), CCL4 (50 ng/ml) and CCL5 (50 ng/ml) 
were applied to LPS- primed U937 cells in the absence of BzATP, no IL-1β was released 
into the cell culture medium (Figure 3 a, c, e). 
LDH levels in cell culture supernatants, as a measure of cell death, remained below 4% 
of the total LDH content of lysed cells. Furthermore, there was no significant variation of 
LDH levels among the analyzed samples (Figure 3 b, d, f). 
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Figure 3. CCL chemokines dose-dependently inhibit the ATP-induced IL-1β release in U937 cells.  Human 
monocytic U937 cells were primed with lipopolysaccharide (LPS; 1 µg/ml, 5 h) and activated with 2’(3’)-
O-(4-benzoylbenzoyl)adenosine-5’- triphosphate (BzATP; 100 µM, 30 min) in the presence of increasing 
CCL chemokine concentrations. The levels of interleukin-1β (IL-1β) and lactate dehydrogenase (LDH) in 
the cell culture supernatant were determined by enzyme-linked immunosorbent assay (ELISA) and 
CytoTox 96® Non-Radioactive Cytotoxicity Assay, respectively. CCL3 (a), CCL4 (c), and CCL5 (e) dose-
dependently and efficiently inhibited the BzATP-induced release of IL-1β. LDH levels throughout all 
performed experiments (b, d, f) did not exceed 4% of the total LDH content of lysed cells. Data are 
presented as individual data points, bars indicate median, whiskers percentiles 25 and 75; n = 4; *p = 0.029, 
in comparison to cells treated with LPS and BzATP. Data were analyzed by non-parametric Kruskal-Wallis 
test followed by the Mann-Whitney rank sum test. p-values below 0.05 were considered as statistically 
significant. 
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3.1.2 CXCL chemokines do not inhibit ATP-dependent IL-1β release 
Tested in the same experimental setting on LPS-primed and ATP stimulated U937 cells, 
chemokines CXCL12 and CXCL16 did not inhibit IL-1β secretion, regardless of the 
concentration used (0.1 to 50 ng/ml) (Figure 4 a, c). Cell death throughout the samples 
was minimal, as reflected by the LDH levels of below 4% of the total LDH content of 
lysed cells (Figure 4 b, d). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. CXCL chemokines do not inhibit the ATP-induced IL-1β release in U937 cells.  
Lipopolysaccharide-primed (LPS; 1 µg/ml, 5 h) human monocytic U937 cells were stimulated with 2’(3’)-
O-(4-benzoylbenzoyl)adenosine-5’- triphosphate (BzATP; 100 µM, 30 min) and CXCL12 or CXCL16 
were simultaneously added in concentrations ranging from 0.1 - 50 ng/ml. The levels of interleukin-1β (IL-
1β) and lactate dehydrogenase (LDH) in the cell culture supernatant were determined by enzyme-linked 
immunosorbent assay (ELISA) and CytoTox 96® Non-Radioactive Cytotoxicity Assay, respectively. 
CXCL12 (a) and CXCL16 (c) did not influence IL-1β secretion to the cell culture medium regardless of the 
applied concentration. LDH levels remained below 4% of the total LDH of lysed cells (b, d). Data are 
presented as individual data points, bars indicate median, whiskers percentiles 25 and 75; n = 4. Data were 
analyzed by non-parametric Kruskal-Wallis test followed by the Mann-Whitney rank sum test. p-values 
below 0.05 were considered as statistically significant. 
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3.2 CCL3-induced inhibition of IL-1β release in human PBMCs 
To test if the inhibitory effect of CCL3 on BzATP-mediated release of IL-1β also applies 
to primary mononuclear cells, experiments were conducted on human PBMCs (Figure 5). 
PBMCs were separated by gradient centrifugation from heparinized blood collected from 
healthy male donors. Adherent LPS-pulsed PBMCs secreted a small amount of IL-1β 
(median 344 pg/ml, range 247 – 468 pg/ml; n = 4) within 30 min, that did not differ from 
the amount of  IL-1β secreted by untreated cells. Application of BzATP (100 µM) induced 
an increase in the IL-1β secretion when compared to untreated cells or cells treated just 
with LPS (median 3.6 ng/ml, range 0.6 – 9.2 ng/ml; n = 4). CCL3, applied in the 
previously determined effective inhibitory concentration of 10 ng/ml significantly 
reduced the ATP-dependent IL-1β release by LPS-primed PBMCs (median 2.2 ng/ml, 
range 0.4 – 4.2 ng/ml; p = 0.029; n = 4) (Figure 5 a). A median 44% reduction in measured 
IL-1β levels was induced when adding CCL3 to LPS-primed and ATP stimulated 
PBMCs. Cell death was slightly higher than in U937 cells with maximum LDH levels not 
surpassing 8% of the total LDH content of lysed cells (Figure 5 b).  
 
 
 
 
 
 
 
 
 
Figure 5: CCL3 inhibits the ATP-induced IL-1β release by human peripheral blood mononuclear cells 
(PBMCs). Blood from healthy volunteers was pulsed with 0.5 ng lipopolysaccharide (LPS)/ml before 
purification of PBMCs. PBMCs were cultured for 3 h, and 2′(3′)-O-(4- benzoylbenzoyl)adenosine-5′-
triphosphate (BzATP; 100 µM) was added for 30 min in the presence or absence of CCL3 (10 ng/ml). 
Interleukin-1β (IL-1β) was measured in cell culture supernatants, and the values obtained in the 
supernatants of cells treated with LPS and BzATP were set to 100%. CCL3 efficiently inhibited BzATP-
induced release of IL-1β by LPS-primed human PBMCs (a). Lactate dehydrogenase (LDH) was measured 
in cell culture supernatant and calculated as a percentage of the total LDH content of lysed cells (b).  Data 
are presented as individual data points, bars indicate median, and whiskers percentiles 25 and 75; n = 4, 
each. Data were analyzed by the Wilcoxon signed-rank test. p-values below 0.05 were considered as 
statistically significant. 
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3.3 Signaling via CCR  
3.3.1 Chemokine receptor expression in U937 and PBMCs 
To elucidate the mechanism underlying the CCL chemokine-induced inhibition on 
ATP-dependent IL-1β release by human monocytes, we first studied the role of their 
cognate receptors. The mRNA expression of receptors corresponding to all previously 
tested chemokines, irrelevant of their IL-1β inhibitory potential, was analyzed by real-
time RT-PCR. This panel of receptors included CCR1, CCR3, CCR5, CXCR4, CXCR6 
and CXCR7. In U937 cells, we were able to detect the mRNA for CCR1, CCR3, CCR5, 
CXCR4 and CXCR7 whereas no mRNA for CXCR6 was detected after 45 cycles of 
amplification. PBMCs, that include both monocytes and lymphocytes, served as a 
positive control and expressed the mRNA of all chemokine receptors, including CXCR6 
(Figure 6). 
No DNA was amplified in negative controls in which cDNA was replaced by dH2O. The 
amplicons resulting from the real-time RT-PCR were separated on 1.5% agarose gels by 
electrophoresis and DNA bands of the expected size (between 100 and 120 bp, as listed 
in Table 7) were detected. DNA sequencing confirmed product identity 
 
Figure 6: Expression of chemokine receptor mRNA in U937 cells and peripheral blood mononuclear cells 
(PBMCs). The mRNA expression of chemokine receptors CCR1, CCR3, CCR5, CXCR4, CXCR6, and 
CXCR7 was investigated in U937 cells by real-time RT-PCR, and the amplicons were separated by gel 
electrophoreses together with a base pair (bp) ladder and detected by GelRedTM Nucleic Acid Dye. PBMCs 
obtained from healthy volunteers served as positive control.  
3.3.2 CCR1 mediates the inhibitory effect of CCL3 on ATP-dependent IL-1β 
release 
To determine whether CCR1 participates in the CCL-induced inhibition of IL-1β release, 
we transfected U937 cells with siRNA targeting CCR1 gene expression. We selected 
CCR1 for gene silencing, because it is a common receptor for all three CCL-chemokines 
included in the study and because the mRNA of this receptor seemed to be more abundant 
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in U937 cells than CCR3 and CCR5 mRNA (Figure 7). Control cells were transfected 
with irrelevant control siRNA. To verify transfection efficiency, cells were harvested 
after 48 h of incubation and the mRNA expression of CCR1 was analyzed using real-rime 
RT-PCR. In contrast to control siRNA, siRNA targeting CCR1 significantly reduced the 
mRNA expression, as shown in Figure 6 (p = 0.029; n = 4). The transfection process itself 
did not alter CCR1 gene expression, as CCR1 mRNA levels were similar in cells that have 
not been transfected and in control siRNA transfected cells. 
Having proven transfection efficiency, U937 cells transfected with control siRNA or with 
siRNA targeting CCR1 were used in IL-1β release experiments, 48 h post-transfection. 
Cells that have not been transfected and that were stimulated with either LPS alone or 
LPS and BzATP were included as controls. BzATP-dependent release of IL-1β by LPS-
primed cells was not impaired and was maintained at equivalent levels in cells transfected 
with either control siRNA or with CCR1 targeting siRNA when compared to cells that 
were not manipulated. ACh, as a classical nicotinic receptor agonist, has been previously 
proven to efficiently inhibit ATP-dependent IL-1β release in human monocytic cells [106]. 
Therefore, ACh was included as a positive control. The ACh-mediated inhibition of IL-
1β release was just as efficient in cells where the CCR1 gene was silenced as in control-
transfected cells (Figure 8 a). In contrast to this, the inhibitory effect of CCL3 was 
significantly blunted in cells with down-regulated CCR1 expression when compared to 
control-transfected cells, as depicted in Figure 8 a (p = 0.008; n = 5).   
LDH concentrations in the cell culture supernatants did not surpass 10% of the total LDH 
content of lysed cells (Figure 8 b). There was also no significant difference in cell death 
between cells transfected with CCR1 targeting siRNA or control-transfected cells. 
Figure 7: Efficient reduction of CCR1 expression in 
U937 cells. U937 cells were transfected with control 
siRNA or with siRNA targeting CCR1. The 
efficiency of the siRNA transfection was verified 48 
hours post-transfection by real-time RT-PCR. A 
significant down-regulation of the CCR1 gene 
expression was obtained for cells treated with siRNA 
targeting CCR1 when compared to those transfected 
with control siRNA. Data are presented as individual 
data points, bars indicate median, and whiskers 
percentiles 25 and 75, n = 4, each. Data were 
analyzed by non-parametric Kruskal-Wallis test 
followed by the Mann-Whitney rank sum test. p-
values below 0.05 were considered as statistically 
significant. 
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Figure 8: The inhibitory effect of CCL3 on ATP-induced IL-1β release by U937 cells is dependent on CCR1. 
U937 cells were transfected with control siRNA or with siRNA targeting CCR1. After 48 hours of 
incubation, these cells were primed with lipopolysaccharide (LPS; 1 µg/ml, 5 h) followed by activation 
with 2′(3′)-O-(4-benzoylbenzoyl)adenosine-5′-triphosphate (BzATP; 100 µM, 30 min). a. Interleukin-1β 
(IL-1β) in the cell culture supernatants was measured by enzyme-linked immunosorbent assay (ELISA). In 
control-transfected cells, CCL3 (10 ng/ml) fully inhibited the BzATP-induced release of IL-1β, whereas 
silencing of CCR1 significantly blunted the inhibitory effect of CCL3. In all experiments, acetylcholine 
(ACh; 10 µM) was included as a positive control. b. Cell death was quantified by measuring lactate 
dehydrogenase (LDH) concentration in cell culture supernatants using the CytoTox 96® Non- Radioactive 
Cytotoxicity Assay. LDH levels were expressed as a percentage from the total LDH content of lysed cells. 
Data are presented as individual data points, bars indicate median, and whiskers percentiles 25 and 75; n = 
5. Data were analyzed by non-parametric Kruskal-Wallis test followed by the Mann-Whitney rank sum 
test. p-values below 0.05 were considered as statistically significant. 
3.3.3 CCR1 is not mandatory for the inhibitory effect of CCL4 and CCL5 on ATP-
dependent IL-1β release 
In the same experimental setting, the previously determined efficient inhibitory 
concentration of CCL4 (50 ng/ml) were applied to LPS-primed and BzATP stimulated 
U937 cells, transfected with either control siRNA or siRNA targeting CCR1. In contrast 
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to CCL3, the inhibitory effect of CCL4 was not influenced by CCR1 gene silencing, 
implying that this receptor in not an essential part of the mechanism leading to CCL4-
induced inhibition of IL-1β release (Figure 9 a). LDH levels remained below 10% of the 
total LDH content of lysed cells (Figure 9 b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: CCR1 silencing does not influence the inhibitory effect of CCL4 on ATP-induced IL-1β release 
by U937 cells. U937 cells were transfected with control siRNA or with siRNA targeting CCR1. After 48 
hours of incubation, these cells were primed with lipopolysaccharide (LPS; 1 µg/ml, 5 h) followed by 
activation with 2′(3′)-O-(4-benzoylbenzoyl)adenosine-5′-triphosphate (BzATP; 100 µM, 30 min). a. 
Interleukin-1β (IL-1β) in the cell culture supernatants was measured by ELISA. In control-transfected cells 
as well as in cells with down-regulated CCR1 gene expression, CCL4 (50 ng/ml) fully inhibited the BzATP-
induced release of IL-1β. In all experiments, acetylcholine (ACh; 10 µM) was included as a positive control. 
b. Cell death was quantified by measuring lactate dehydrogenase concentration in cell culture supernatants 
using the CytoTox 96® Non- Radioactive Cytotoxicity Assay. LDH levels were expressed as a percentage 
from the total LDH content of lysed cells. Data are presented as individual data points, bars indicate median, 
and whiskers percentiles 25 and 75; n = 4. Data were analyzed by non-parametric Kruskal-Wallis test 
followed by the Mann-Whitney rank sum test. p-values below 0.05 were considered as statistically 
significant. 
 
The involvement of CCR1 in the CCL5-induced inhibition of ATP-dependent IL-1β 
release was also tested by down-regulating CCR1 gene expression. CCL5 fully inhibited 
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BzATP-dependent IL-1β secretion in cells transfected with control siRNA as well as in 
cells transfected with CCR1-targeting siRNA, showing just as in the case of CCL4, no 
essential contribution of the CCR1 receptor signaling to its inhibitory effect (Figure 10 
a). The viability of the cells was not impaired (Figure 10 b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: CCR1 silencing does not influence the inhibitory effect of CCL5 on ATP-induced IL-1β release 
by U937 cells. U937 cells were transfected with control siRNA or with siRNA targeting CCR1. After 48 
hours of incubation, these cells were primed with lipopolysaccharide (LPS; 1 µg/ml, 5 h) followed by 
activation with 2′(3′)-O-(4-benzoylbenzoyl)adenosine-5′-triphosphate (BzATP; 100 µM, 30 min). a. 
Interleukin-1β (IL-1β) in the cell culture supernatants was measured by ELISA. In control-transfected cells 
as well as in cells with down-regulated CCR1 gene expression, CCL5 (50 ng/ml) fully inhibited the BzATP-
induced release of IL-1β. In all experiments, acetylcholine (ACh; 10 µM) was included as a positive control. 
b. Cell death was quantified by measuring lactate dehydrogenase concentration in cell culture supernatants 
using the CytoTox 96® Non- Radioactive Cytotoxicity Assay. LDH levels were expressed as a percentage 
from the total LDH content of lysed cells. Data are presented as individual data points, bars indicate median, 
and whiskers percentiles 25 and 75; n = 4. Data were analyzed by non-parametric Kruskal-Wallis test 
followed by the Mann-Whitney rank sum test. p-values below 0.05 were considered as statistically 
significant. 
CCL3 was selected for the following elucidation of the signaling pathway.  
CHAPTER 3                                                                                                       RESULTS 
 48 
3.4 Involvement of nAChRs 	
3.4.1 CCL3 signaling involves nAChRs 
We hypothesized that chemokine-induced inhibition of IL-1β secretion is mediated by a 
cholinergic mechanism involving nAChRs, similar to the one described by Hecker et al. 
and Richter et al. [106, 233]. These two studies conducted in our laboratory established that 
stimulation of the α7 and α9/α10 nAChR subunits triggers a cholinergic pathway that 
prevents LPS-primed monocytes from secreting IL-1β upon receiving an ATP stimulus. 
We therefore set out to verify whether CCL3 signaling also involves these nAChR 
subunits by using a panel of nAChR antagonists that either preferentially or specifically 
act upon nAChR containing subunits α7 and α9/α10. 
The usual set of controls showed an adequate and significant release of IL-1β by U937 
cells incubated for 5 h with LPS and stimulated for 30 min with BzATP compared to 
untreated or LPS-primed cells. The inhibitory effect of CCL3 on the BzATP-induced 
release of IL-1β by U937 cells was indeed sensitive to mecamylamine (100 µM; p = 
0.001, n = 5 versus n = 9), a general nAChR antagonist [90, 259]. Similarly, α-bungarotoxin 
(1 µM; p = 0.001, n = 5 versus n = 9) and strychnine (10 µM; p = 0.001, n = 5 versus n = 
9), reagents that preferentially antagonize nAChR containing subunits α7 and α9 [171, 281] 
were efficient (Figure 11 a). To differentiate between those subunits, we made use of the 
antagonistic peptides [V11L; V16D]ArIB (500 nM), specific for nAChR containing an 
α7 subunit, and RgIA4 (200 nM), an antagonist of α9/α10 nAChR [112, 240, 300]. Both 
peptides antagonized the effect of CCL3 (p = 0.003, n = 5 versus n = 9), suggesting that 
signal transduction involves nAChR subunits α7 and α9/α10 (Figure 11 a). These nAChR 
subunits have been previously shown to be expressed by U937 cells and by human 
monocytes [106, 131]. The viability of the cells in this set of experiments remained 
unimpaired, regardless of the applied reagents with LDH values remaining below 4% of 
the total LDH content of lysed cells (Figure 11 b). 
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Figure 11: CCL3 signaling involves nicotinic acetylcholine receptors. Human monocytic U937 cells were 
primed with lipopolysaccharide (LPS; 1 µg/ml, 5 h) and activated with 2′(3′)-O-(4-
benzoylbenzoyl)adenosine-5′-triphosphate (BzATP; 100 µM, 30 min). The release of IL-1β to the cell 
culture supernatant was measured by ELISA. a. Nicotinic antagonists mecamylamine (Mec; 100 µM), α-
bungarotoxin (α-Bun; 1 µM), and strychnine (Stry; 10 µM), as well as conotoxin-derived peptides 
[V11L; V16D]ArIB (200 nM) and RgIA4 (200 nM), significantly reversed the inhibitory effect of CCL3. 
b. Lactate dehydrogenase (LDH) levels remained under 4% of the total LDH content of lysed cells. Data 
are presented as individual data points, bars indicate median, and whiskers percentiles 25 and 75. Data were 
analyzed by non-parametric Kruskal-Wallis test followed by the Mann-Whitney rank sum test. p-values 
below 0.05 were considered as statistically significant. 
3.4.2 Nigericin-mediated release of IL-1β is not inhibited by CCL3 
As a pore-forming bacterial toxin, nigericin induces K+ efflux that activates the 
inflammasome independent of BzATP [182]. As expected, stimulation of LPS-primed 
U937 cells with nigericin, in the presence of the ATP-cleaving enzyme apyrase resulted 
in a significant increase of IL-1β levels in the cell culture supernatant, when compared to 
untreated or LPS-treated cells (p = 0.02, n = 6). The addition of CCL3 did not affect the 
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nigericin-induced secretion of IL-1β (Figure 12 a). LDH levels were even and did not 
exceed 4% of the total LDH content of lysed cells (Figure 12 b). 
 
 
 
 
 
 
 
 
 
Figure 12: CCL3 does not inhibit the ATP-independent IL-1β release by U937 cells. Human monocytic 
U937 cells were primed with lipopolysaccharide (LPS; 1 µg/ml, 5 h) and activated with the pore-forming 
bacterial toxin nigericin (50 µM) in the presence of apyrase (0.5 U/ml). a. The release of interleukin-1β (IL-
1β) into the cell culture supernatant was measured by enzyme-linked immunosorbent assay (ELISA). 
Nigericin induced the release of IL-1β by LPS-primed U937 cells, but the chemokine CCL3 (10 ng/ml) did 
not impair the nigericin-triggered release of IL-1β (n = 6). b. Lactate dehydrogenase (LDH) levels remained 
below 4% of the total LDH content of lysed cells. Data are presented as individual data points, bars indicate 
median, and whiskers percentiles 25 and 75. Data were analyzed by non-parametric Kruskal-Wallis test 
followed by the Mann-Whitney rank sum test. p-values below 0.05 were considered as statistically 
significant. 
3.5 Release of soluble factors  
We wanted to solve the question of how CCR activation links to cholinergic signaling. 
As at least some of the effective nicotinic antagonists such as α-bungarotoxin and RgIA4 
probably do not enter the cytoplasm of the target cell due to their size and hydrophobicity, 
we assume that relevant nAChRs are localized in the plasma membrane. Hence, we 
postulated the involvement of soluble small nicotinic agonists that are released to the cell 
culture medium in response to CCL3.  
To test this hypothesis, LPS-primed U937 cells were stimulated with CCL3 (10 ng/ml), 
and conditioned cell culture medium was harvested 30 min later. A low molecular weight 
fraction of the conditioned cell culture medium devoid of CCL3 was produced by 
ultrafiltration with a cut-off of 3.5 kDa (Figure 13 a).  
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Figure 13: Release of small mediators in response to CCL3. U937 cells were primed with 
lipopolysaccharide (LPS; 1 µg/ml, 5 h) and activated with 2′(3′)-O-(4- benzoylbenzoyl)adenosine-5′-
triphosphate (BzATP; 100 µM, 30 min). An ultrafiltrate (UF) was produced containing the low molecular 
mass fraction (<3 kDa) of the cell culture supernatant (S) of LPS-primed U937 cells treated with CCL3 (10 
ng/ml) for 30 min. For the production of control UF, CCL3 was added to the cell-free supernatant of LPS-
primed U937 cells shortly before ultrafiltration. a. The release of interleukin-1β (IL-1β) to the cell culture 
supernatant was measured by enzyme-linked immunosorbent assay (ELISA). CCL3, which was included 
as a positive control, inhibited the BzATP-induced release of IL-1β. Control UF had no effect on the 
BzATP-induced release of IL-1β by LPS-primed U937 cells, whereas the UF significantly reduced the IL-
1β release. The inhibitory effect of the UF was reversed by antagonistic peptides [V11L; V16D]ArIB (200 
nM) and RgIA4 (200 nM). b. Cell death was quantified through lactate dehydrogenase (LDH) measurement 
and remained at levels below 6% of the total LDH content of lysed cells. Data are presented as individual 
data points, bars indicate median, and whiskers percentiles 25 and 75. Data were analyzed by non-
parametric Kruskal-Wallis test followed by the Mann-Whitney rank sum test. p-values below 0.05 were 
considered as statistically significant.  
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As a control, conditioned medium was produced in the absence of CCL3 but CCL3 was 
added to the cell-free supernatant shortly before ultrafiltration. In line with our 
hypothesis, the ultrafiltrate of conditioned medium significantly inhibited the 
BzATP-stimulated release of IL-1β by LPS-primed U937 cells, whereas the ultrafiltrate 
of the control conditioned medium was ineffective (p = 0.016; n = 4 versus n = 5) (Figure 
13 a). We wondered if this small mediator acts as a nicotinic agonist at nAChR subunits 
and were indeed able to demonstrate that the effect of conditioned medium is antagonized 
by peptides [V11L; V16D]ArIB and RgIA4 (p = 0.029; n = 4 each) that are specific for 
nAChR subunits α7 and α9, respectively (Figure 13 a). These results suggest that CCL3 
induces the secretion of nicotinic agonists by U937 cells. Cell viability was not affected 
in these experiments as LDH levels, determined using the  CytoTox 96® Non- Radioactive 
Cytotoxicity Assay remained below 6% of the total LDH content of lysed cells (Figure 
13 b). 
 
Figure 14. Ultrafiltration efficiently depleted CCL3 from the conditioned cell culture supernatant. U937 
cells were primed with lipopolysaccharide (LPS; 1 µg/ml, 5 h) and activated with 2′(3′)-O-(4- 
benzoylbenzoyl)adenosine-5′-triphosphate (BzATP; 100 µM, 30 min). An ultrafiltrate (UF) was produced 
containing the low molecular mass fraction (<3 kDa) of the cell culture supernatant (S) of LPS-primed 
U937 cells treated with CCL3 (10 ng/ml) for 30 min.  The UF and the high molecular mass fraction (HF) 
obtained by ultrafiltration were separated in a 15% SDS- polyacrylamide gel along with a molecular mass 
marker (M) followed by silver staining. The arrow is pointing to the band corresponding to CCL3. Proteins 
with higher molecular mass are bovine serum albumin (66.5 kDa) and its contaminations that were added 
to the CCL3 preparation for stabilization.  
To verify whether the ultrafiltration process efficiently depleted CCL3 from the 
conditioned cell culture supernatant, the ultrafiltrate and the high molecular mass fraction 
obtained by ultrafiltration were separated in a 15% SDS- polyacrylamide gel along with 
molecular mass standards. The conditioned cell culture medium, harvested 30 min after 
CCL3 application was used as a control. Because of the low amount of CCL3 
(approximately 20 ng) used for the conditioning of the cell culture supernatant, the protein 
bands were detected by silver staining. A protein band corresponding to CCL3 was 
detected in the conditioned supernatant and was enriched as expected in the high 
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molecular mass fraction, but absent from the ultrafiltrate, proving the efficiency of 
ultrafiltration. (Figure 14). The protein bands in the higher molecular mass range are at 
least in part due to bovine serum albumin that was used for stabilization of CCL3. The 
silver staining was kindly performed by Dariusz Zakrzewicz, Department of 
Biochemistry, Faculty of Medicine, Giessen, Germany. 
3.6 Involvement of iPLA2β  
Knowing from previous studies conducted in our laboratory that phospholipase-
dependent metabolites of phosphatidylcholines can engage nAChRs [106, 233, 311] and that 
chemokine receptors signal through downstream phospholipases, we tested whether 
iPLA2 links CCL3 signaling to the cholinergic inhibition of IL-1β release. For this 
purpose, we used ATK (50 µM), an inhibitor of cytosolic, calcium-dependent (cPLA2) 
and calcium-independent (iPLA2) classes of phospholipase A2 [157, 266]. ATK enabled 
BzATP-induced IL-1β release in despite of the presence of CCL3 (p = 0.029, n = 4; Figure 
15 a). BEL (50 µM), a more specific inhibitor of iPLA2 [6], was also effective, suggesting 
that iPLA2 plays an essential role (p = 0.029, n = 4; Figure 15 a) in the CCL3-mediated 
inhibition of IL-1β secretion by LPS-primed and ATP-stimulated U937 cells. The 
included controls showed a significant release of IL-1β by LPS-primed U937 cells upon 
activation with BzATP that was reversed by the inhibitory effect of CCL3. LDH levels 
were minimal, proving that cell viability was not affected throughout the experiment 
(Figure 15 b).  
 
 
 
 
 
 
 
 
Figure 15. CCL3 signaling involves calcium-independent phospholipase A2 (iPLA2). Human monocytic 
U937 cells were primed with lipopolysaccharide (LPS; 1 µg/ml, 5 h) and activated 2′(3′)-O-(4-
Benzoylbenzoyl)adenosine-5′-triphosphate (BzATP; 100 µM, 30 min). a. The release of IL-1β to the cell 
culture supernatant was measured by enzyme-linked immunosorbent assay (ELISA). CCL3 (10 ng/ml) 
inhibited the release of IL-1β in response to BzATP. The general PLA2 inhibitor arachidonyl 
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trifluoromethyl ketone (ATK) and the specific iPLA2 inhibitor bromoenol lactone (BEL) reversed CCL3-
dependent inhibition. b. Cell death was quantified through lactate dehydrogenase (LDH) measurement and 
remained at levels below 4% of the total LDH content of lysed cells. Data are presented as individual data 
points, bars indicate median, and whiskers percentiles are 25 and 75, n = 4, each. Data were analyzed by 
non-parametric Kruskal-Wallis test followed by the Mann-Whitney rank sum test. p-values below 0.05 
were considered as statistically significant. 
To further assess the importance of iPLA2 for the inhibitory effect of CCL3 on IL-1β 
secretion by LPS-primed and BzATP-activated U937 cells, we silenced iPLA2β 
expression by transfecting U937 cells with PLA2G6 targeting siRNA via electroporation. 
Cells transfected with irrelevant siRNA and untreated U937 cells were included in the 
experiments as controls and had similar PLA2G6 mRNA expression levels. Transfection 
efficiency was first verified by comparing PLA2G6 gene expression levels in cells 
transfected with siRNA targeting the gene of interest (PLA2G6) with control-transfected 
cells by using real-time RT-PCR. A significant down-regulation of the PLA2G6 gene was 
detected, proving transfection efficiency (Figure 16, p = 0.029, n = 4). The expression of 
the housekeeping gene HMBS, used as a positive control in the real time RT-PCR 
experiments was not affected by siRNA transfection. 
  
The effects of PLA2G6 silencing were also verified at the protein level by Western 
blotting. U937 cells were lysed, and proteins were separated on 10% SDS-polyacrylamide 
gels, then transferred onto polyvinylidene membranes together with dual color protein 
standards. iPLA2β immobilized on the membranes was detected by polyclonal rabbit 
antibodies to iPLA2β (1 : 5000), then detected with secondary HRP-labeled antibodies 
(1 : 5000), lumi-light substrate, and high-performance chemiluminescence films. β-actin 
served as a loading control and was detected by mouse monoclonal antibodies to β-actin 
(1 : 50000) and the same secondary antibody and substrate. The optical density (OD) of 
the immunopositive bands was measured, and the ratio of the OD of iPLA2β and β-actin 
Figure 16: Efficient PLA2G6 silencing by siRNA 
transfection. Expression of iPLA2 by U937 cells 
was silenced by siRNA (PLA2G6). Silencing of 
PLA2G6 expression was efficient as revealed by 
real-time RT-PCR. Values obtained for cells 
treated with siRNA targeting PLA2G6 were 
statistically compared to those transfected with 
control siRNA. Data are given as arbitrary units, 
bars indicate median, and whiskers percentiles 25 
and 75, n = 4. Data were analyzed by non-
parametric Kruskal-Wallis test followed by the 
Mann-Whitney rank sum test. p-values below 
0.05 were considered as statistically significant.  
CHAPTER 3                                                                                                       RESULTS 
 55 
was determined, showing a significant decrease in the iPLA2β levels in cells with silenced 
PLA2G6 expression compared to control-transfected cells (Figure 17 b, p = 0.029, n = 4). 
A typical result of 4 experiments is shown in Figure 17 a with the protein band 
corresponding to iPLA2β detected at about 80 kDa, that is visibly attenuated in cells 
transfected with siRNA targeting PLA2G6 when compared to untreated or control-
transfected cells.  
 
 
 
 
 
 
Figure 17: Efficient silencing of iPLA2β expression in U397 cells by RNA interference. U937 cells were 
transfected with either control siRNA or siRNA targeting PLA2G6. a. Silencing of PLA2G6 expression 
resulted in a significant decrease in iPLA2β levels as shown by Western blotting. β-actin served as a loading 
control. b. The optical density (OD) of the immunopositive bands was measured, and the ratio of the OD 
of iPLA2β and β-actin was formed. Values obtained for cells treated with siRNA targeting PLA2G6 were 
statistically compared to those transfected with control siRNA. Data are given as arbitrary units, bars 
indicate median, and whiskers percentiles 25 and 75, n = 4. Data were analyzed by non-parametric Kruskal-
Wallis test followed by the Mann-Whitney rank sum test. p-values below 0.05 were considered as 
statistically significant. 
The U937 cells with down-regulated iPLA2β expression were used in IL-1β release 
experiments. The obtained IL-1β levels were compared to those resulting from cells 
transfected with control siRNA. BzATP-dependent IL-1β secretion was unimpaired 
regardless if the LPS-primed cells were transfected or not. CCL3 showed a fully 
inhibitory effect in untreated cells and control-transfected cells but this inhibitory effect 
was significantly blunted in the case of cells that were transfected with siRNA targeting 
PLA2G6 (Figure 18 a; p = 0.029, n = 4). LDH levels remained below 7% of the total LDH 
content of lysed cells (Figure 18 b). There was no significant difference between the LDH 
levels detected in the supernatants of untreated cells and those of transfected cells. 
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Figure 18: CCL3 signaling involves calcium-independent phospholipase A2β (iPLA2β). Human monocytic 
U937 cells were primed with lipopolysaccharide (LPS; 1 µg/ml, 5 h) and activated 2′(3′)-O-(4-
Benzoylbenzoyl)adenosine-5′-triphosphate (BzATP; 100 µM, 30 min). a. The release of interleukin-1β (IL-
1β) to the cell culture supernatant was measured by enzyme-linked immunosorbent assay (ELISA). After 
treatment with siRNA targeting PLA2G6 expression, the inhibitory effect of CCL3 on IL-1β release was 
blunted. In untreated control cells and upon transfection of control siRNA, CCL3 was effective. b. LDH 
levels remained below 7% of the total LDH content of lysed cells and did not significantly vary between 
individual samples. Data are presented as individual data points, bars indicate median, and whiskers 
percentiles 25 and 75, n = 4, each. Data were analyzed by non-parametric Kruskal-Wallis test followed by 
the Mann-Whitney rank sum test. p-values below 0.05 were considered as statistically significant. 
Taken together, these results are in line with the hypothesis that iPLA2β is involved in 
CCL3 signaling and might be a key enzyme for the production of the bioactive soluble 
factor(s) that presumably stimulate nAChR. 
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4 Discussion 
4.1 The rationale behind a cholinergic anti-inflammatory effect of 
chemokines 
In this study, we provide evidence for a novel immunomodulatory property of CCL-
chemokines, that makes use of nAChR in order to control the ATP-induced release of IL-
1β into the appropriate biological compartment. 
A lot of data has been gathered recently on the cholinergic system of immune cells, 
supporting its critical contribution to the regulation of immune function and suggesting 
novel niches for therapeutic manipulation. The emphasis was put on the anti-
inflammatory cholinergic reflex advanced by Tracey’s group, encompassing vagal-
immune interactions that result in a down-regulation of pro-inflammatory cytokine 
synthesis by splenic macrophages [37, 276, 294]. However, cholinergic macrophages are 
not the only ones equipped to respond to cholinergic stimuli, as gene expression for 
nAChR subunits was detected in all human mononuclear cells and in leukemic cell lines 
[131, 247]. As neuroanatomically no immune organ, spleen included, disposes of a direct 
parasympathetic innervation [189], most of the nAChR-equipped mononuclear cells 
would be out of reach for vagal ACh. An alternative explanation, that complies with the 
lack of parasympathetic innervation of the spleen, was provided by Rosas-Balina in 2011, 
supporting Tracey’s concept of an anti-inflammatory cholinergic reflex [241]. As stated 
by the authors, efferent signal transmission occurs via the splenic nerves that release 
norepinephrine, in response to which a specific subset of T-cells releases ACh that acts 
on the a7 nAChRs of splenic macrophages, suppressing TNF-a expression [200, 241]. 
Introducing the CD4+ T cells as the source of ACh uncovered further controversial issues 
[30], such as lacking evidence for a synapse between sympathetic nerves and CD4+ T 
cells, so that a final verdict in the matter of the vagal anti-inflammatory reflex is still 
pending.  
Meanwhile, a ready and able ACh producing machinery was described in immune cells 
as distant from the spleen as alveolar macrophages [299], prompting the idea of local, non-
neural cholinergic mechanisms that control immune cell function. Furthermore, ACh 
production by certain immune cells, including machrophages and DCs, was shown to be 
induced by immune challenging events such as exposure to the classic TLR4 agonist, LPS 
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[78, 228]. These innate immune cells might therefore be able to directly engage their 
cholinergic equipment at the site of injury, as a negative feed-back mechanism that 
contains local inflammation. Further supporting this hypothesis, Hecker et al. [107] 
demonstrated on allogenic renal grafts that endogenous ACh supresses the release of 
proinflammatory cytokine IL-1β by allograft monocytes. Immune challenge, in this case 
in the form of acute transplant rejection, also lead to increased ACh production and 
release. Bringing forward the arguments of a short ACh half-life due to its rapid 
degradation by ACh esterases [159, 255] and of surgically denervated grafts that exclude 
neuronal ACh spillage, the detected ACh in mononuclear leukocytes isolated from the 
vascular bed of renal allografts was argued to be of non-neuronal origin [107]. 
Building upon these results, further compounds have been identified that act as nAChR 
agonists, causing an inhibition of inflammasome-mediated IL-1β maturation and 
secretion by human monocytes. Among these is lysophosphatidylcholine (LPC), a 
common PLA2-dependent metabolite of phosphatidylcholines [311]. It has long been 
acknowledged that PLA2 plays an essential role in inflammation by generating lipid 
mediators, that thus far are recognized to have both pro- and anti-inflammatory effects 
[61, 252, 253]. Several isoforms of the PLA2 family are known to act as downstream 
mediators of chemokine receptors [49, 284]. A further compound, β-nicotinamide adenine 
dinucleotide (β-NAD), released during inflammation by damaged cells, by interacting 
with P2Y receptors on human monocytes also inhibits IL-1β synthesis, by engaging a 
very similar cholinergic signaling pathway [109]. The P2Y receptors are part of the family 
of GPCRs, as are chemokine receptors [4, 289]. 
Chemokines play their central role in coordinating the spaciotemporal dynamic of 
inflammatory cells during tissue injury. Considering that their signaling pathways have 
at least some common elements with the above mentioned compounds, we set out to 
investigate whether chemokines themselves might engage the same cholinergic 
mechanism to reduce IL-1β release by human monocytes. Such immunomodulatory 
action might be of utmost importance and pathophysiologically reasonable at sites of 
endothelial disruption, where spillage of inflammasome activating substances, such as 
ATP, might lead to premature IL-1β release from monocytes.   
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4.2 Anti-inflammatory effects of CCL-chemokines 
The experimental rat renal allografts delivered the fundament for the postulated non-
neuronal cholinergic IL-1β inhibiting mechanism, with all the advantages of an in vivo 
model, yet it depicts a rather particular immune reaction and it is difficult to reproduce ex 
vivo. Subsequent experiments elucidating further aspects of the nAChR-mediated IL-1β 
inhibition were successfully translated to and carried out on U937 cells. The current study 
therefore also employs this human monocytic cell line as well as freshly isolated primary 
mononuclear cells. 
Our hypothesis presumes that chemokines prevent monocytes receiving both chemotactic 
and inflammasome-activating signals from prematurely releasing their IL-1β load before 
having crossed the endothelial barrier into the injured tissue. It is known that monocyte 
emigration from the bone marrow is CCR2-dependent, driven by a CCL2 chemotactic 
gradient [118, 258]. CCR1 and CCR5, as shown by in vitro transmigration assays as well 
as in vivo experiments, have non-redundant roles in monocyte locomotion on the 
endothelial surface, where they mediate the arrest and spreading of the monocytes in the 
presence of shear flow, before transmigration [70, 296, 313]. The highest concentration of 
ATP leaked from inflamed and injured tissues into the circulation would likely be reached 
at the endothelial interface. Therefore, we chose CCL3, CCL4 and CCL5 as shared 
ligands of CCR1 and CCR5 to test their inhibitory potential on ATP-induced monocyte 
IL-1β secretion. 
All three of the tested ligands (CCL3, CCL4 and CCL5) effectively and dose-dependently 
inhibited IL-1β secretion from LPS-primed, BzATP-stimulated U937 cells, with CCL3 
standing out as the most potent inhibitor. The IC50 values were in the range of 1 – 5 ng/ml 
for CCL3 and CCL4 and about 10 ng/ml for CCL5. These IC50 values are in the range of 
the EC50 values typical for the activation of their cognate receptors [280].  
Several studies describe CCR1, CCR5 and their corresponding ligands to be involved in 
immune events that prevent or at least attenuate a further propagation of the inflammatory 
response. None of these imply direct inhibition of pro-inflammatory cytokine production, 
as our results do. D’Amico et al. reported that CCR1, CCR2 and CCR5 on the surface of 
monocytes can be uncoupled from further down-stream signaling by IL-10, with the 
consequence of an impaired monocyte recruitment. The deactivated receptors then act as 
functional decoys for their corresponding ligands, preventing them from exerting their 
pro-inflammatory chemotactic functions [56].  
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A further example for CCR1 mediating anti-inflammatory effects comes from a mouse 
model of nephrotoxic nephritis where CCR1 deficiency unexpectedly exacerbated the 
course of disease causing greater renal impairment. The results were attributed to an 
enhanced mononuclear TNF-α production and increased Th1 immune response of CCR1-
deficient mice [274]. Discrepant findings were delivered by a model of pulmonary 
inflammation secondary to acute pancreatitis that CCR1-deficient mice were protected 
from, the authors associating this effect with decreased TNF-α levels [86].  
Examples supporting either pro- or anti-inflammatory effects resulting from the 
interaction of CCR1 and CCR5 with their corresponding ligands are abundant. 
Seemingly, this plasticity of their effect has much to do with the context or with the 
inflammatory microenvironment that surrounds the immune cells that express these 
chemokine receptors. Another point to consider is that most inflammation models that 
generate results are murine models and that mouse and human orthologs may differ in 
biological function. For example, human CCL3 and CCL5 unlike their murine 
counterparts are poor agonists for neutrophils, meaning that the parallels drawn between 
mouse disease models and human pathology will at least partially be blurred by neutrophil 
activity [53, 310].  
Knowing that cell lines can also considerably differ from primary cells, we sought to 
confirm our result on freshly isolated PBMCs from healthy donors. IL-1β released by 
LPS-pulsed and ATP-stimulated PBMCs was significantly reduced when adding CCL3, 
leading us to conclude that primary mononuclear cells are equipped with and can engage 
the inhibitory pathway triggered by CCL chemokines. CCL3 applied in a concentration 
of 10 ng/ml reduced the IL-1β secretion of U937 cells to baseline levels compared to a 
48% reduction achieved for primary cells.  CCL3 induced IL-1β inhibition in LPS-pulsed 
and ATP-stimulated PBMCs was therefore less effective but significant nonetheless (p = 
0.029).  
4.3 No effect of CXCL-chemokines on ATP-induced monocytic IL-1β 
secretion 
 
Monocytes also possess a panel of receptors for CXCL chemokines that includes CXCR1, 
CXCR2, CXCR4 and CXCR7 [18]. CXCR1 and CXCR2 are prototypic neutrophil 
chemotactic receptors and the physiologic relevance of their expression on the surface of 
monocytes has not thoroughly been investigated. CXCL12 (stromal cell-derived factor-
1, SDF-1), the ligand for CXCR4 and CXCR7, is believed to be the primordial 
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chemokine, having evolved as a regulating signal for stem cell homing [185]. Primarily a 
homeostatic chemokine, it can be induced as a chemoattractant for monocytes, B cell 
precursors and T-cells. Most studies define CXCL12 therefore as being a pro-
inflammatory cytokine with implications in various autoimmune diseases as well as in 
cardiovascular pathologies involving a pro-inflammatory milieu such as 
ischemia/reperfusion injuries, thrombosis or the pro-angiogenetic tumor environment [20, 
33, 315]. One of the few experiments providing evidence of CXCL12 exerting an anti-
inflammatory effect involves a murine model of autoimmune encephalitis, in which 
CXCL12 administration lead to rapid disease remission. The observed effect was 
attributed to the polarization of CD4+ T cells and macrophages to become IL10high-
producing regulatory T cells (Tregs) [176].  
Due to the fact that its encoding gene is unique in that it shows an equidistant sequence 
homology to both CCL and CXCL chemokines, we considered CXCL12 to be a good 
candidate to test whether the cholinergic inhibitory mechanism is restricted to the domain 
of CCL chemokines. In our experiments, CXCL12 regardless of the applied concentration 
(0.1 to 50 ng/ml) did neither inhibit nor increase IL-1β secretion from LPS- and BzATP-
stimulated U937 cells. 
CXCL16 is not involved in monocyte migration and its corresponding receptor, CXCR6, 
is not expressed on the surface of myeloid cells but on T cells [18]. This fact was confirmed 
by the real-time RT-PCR analysis that showed no mRNA expression for CXCR6 in U937 
cells as opposed to the PBMC fraction, that also includes lymphocytes (Figure 6). This 
made CXCL16 a valid negative control for the dose-response experiments conducted with 
CCL chemokines and CXCL12 on U937 cells. As expected, CXCL16 had no inhibitory 
effect on the IL-1β release from LPS-primed, ATP-stimulated U937 cells.  
4.4 CCL-mediated IL-1β inhibition commences with CCL/CCR-
interaction 
We further investigated whether the described pathway inhibiting the ATP-induced 
secretion of IL-1β is triggered by the canonical interaction of  CCL3, CCL4 or CCL5 with 
their cognate GPCRs. CCR1, CCR3 and CCR5 mRNA expression was detected, as 
expected, in both U937 and primary PBMCs, with CCR1 being expressed most 
abundantly and chosen therefore for further pathway elucidation. Down-regulation of 
CCR1 expression diminished the inhibitory potential of CCL3 on IL-1β release but did 
not influence that of CCL4 and CCL5. These results suggest that the anti-inflammatory 
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effect of CCL3 is at least in part mediated by its interaction with CCR1. The fact that 
CCR1 silencing did not fully counteract the inhibitory effect of CCL3 may be explained 
by the fact that siRNA-treatment did not fully abolish the expression of CCR1 and/or that 
apart from CCR1 other chemokine receptors such as CCR3 and CCR5 are involved. 
Though all three of the studied chemokines bind to CCR1, they do so at different 
affinities. In fact, only a N-terminally truncated form of CCL4, secreted by activated 
human lymphocytes acts as a low-affinity CCR1 ligand, whereas the full-length variant 
does not bind to the receptor at all [98]. This does explain why CCR1 silencing in our 
experiments did not attenuate the inhibitory effect of CCL4 on ATP-mediated IL-1β 
release. Since there is a level of redundancy in the chemokine/receptor system of CCL3, 
CCL4, CCL5/CCR1, CCR3, CCR5, silencing of each or of any combination of the three 
receptors would probably be necessary to determine how CCL4 or CCL5 trigger the 
inhibitory mechanism. 
4.5 Linking CCL/CCR interaction to the inhibition of ATP-induced 
IL-1β release through iPLA2β enzymatic activity 
We focused on the CCL3/CCR1 interaction to further investigate the pathway leading to 
the inhibition of ATP-induced IL-1β release. Ligand-binding to the CCR1 receptor 
triggers the classic chemokine signaling pathway through the Gi/o class of G proteins, 
context-dependently selecting one of various potential downstream phospholipid-
modifying enzymes including phospholipase A2, C or D, MAPKs and tyrosine kinases 
[190].  
The role of signal-activated PLA2 enzymes as down-stream mediators of chemokine 
receptor signaling has recently shifted into focus, when they emerged as regulators of 
monocyte chemotaxis [46, 152, 180]. Monocytes dispose of secretory (sPLA2), cPLA2 and 
iPLA2 classes of phospholipase A2, that generate free fatty acids and lysophospholipids 
by hydrolysing phospholipids [61]. Unlike other PLA2 members, that exert their 
enzymatic activity at a specific position in the phospholipid structure, iPLA2 has no 
substrate preference and can act as a lysophospholipase, transacylase or thioesterase [183]. 
Therefore, the products of its enzymatic activity are highly varied and their biologic 
activity and significance not fully understood.  
Most studies observing iPLA2, more specifically iPLA2β involvement in monocyte 
chemotaxis are modeled on the chemotactic activity of CCL2 during its interaction with 
its cognate CCR2 receptor, leaving this aspect of CCR1/CCR3 post-receptor signaling 
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uncharacterized. Monocytes rendered deficient in iPLA2β no longer migrated along the 
CCL2 gradient, though chemotaxis could be restored by lysophosphatidic acid (LPA) 
[180]. This lipid metabolite of iPLA2β was therefore considered essential for monocyte 
chemotaxis, especially in terms of speed and directionality, that involved rearranging of 
the cytoskeleton for controlling the direction of forward membrane protrusion and cell 
orientation. The mechanism through which iPLA2β coordinates these changes in 
monocyte morphology includes its translocation from the cytosol to the plasma 
membrane, where it colocalizes with proteins regulating actin organization and is 
provided with substrates for its enzymatic activity. The resulting LPA was speculated to 
leave the cell in order to further deliver the chemotactic signal by interacting with LPA 
receptors on the surface of  monocytes thus creating a membrane traversing signaling 
path [47, 180].  
We also confirmed the importance of iPLA2β mediation in the signal transduction starting 
from CCL3 engaging its receptor and leading to the inhibition of ATP-mediated IL-1β 
release. This was achieved both by silencing iPLA2β expression using small interfering 
RNA and by blocking its activity using ATK or BEL. The inhibitory effect of CCL3 on 
IL-1β secretion was blunted in both instances, proving that iPLA2β is a necessary 
component of our chemokine-induced anti-inflammatory mechanism. 
Similar to the chemotactic signaling pathway of CCL2, we assumed that metabolites 
resulting from the enzymatic activity of iPLA2β on lipid substrates from the cell 
membrane leave the cell and interact with receptors on the surface of monocytes. As 
mentioned before, our work group has already identified a broad panel of such 
metabolites, including LPC, glycerophosphocholine (G-PC) and PC, that act as nicotinic 
agonists of monocytic nAChRs that control the ion channel function of the P2X7R [106, 
233, 311]. Hence, it is conceivable that a similar iPLA2β -derived lipid mediator can 
cholinergically inhibit ATP-induced release of IL-1β downstream of the CCL3/CCR1 
interaction. The supernatant of CCL3-stimulated U937 cells was subjected to 
ultrafiltration in order to deplete it of residual CCL3. The ultrafiltrate significantly 
inhibited the BzATP-stimulated release of IL-1β, confirming that a mediator with a 
molecular molecular mass below 3.5 kDa was releasead extracellularly as a result of 
CCL3/CCR1 interaction and that this mediator was responsible for the inhibitory effect 
of CCL3 on ATP-induced IL-1β release. The efficacy of the ultrafiltration process in 
removing residual CCL3, was confirmed by silver staining that proved the ultrafiltrate to 
be devoid of CCL3 and by the fact that the control ultrafiltrate remained ineffective in 
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inhibiting BzATP-induced IL-1β release. The nature of the product, resulting from 
iPLA2β enzymatic activity, involved in our anti-inflammatory mechanism is still to be 
determined. 
There are several other reports placing iPLA2-dependent fatty acids and 
lysophospholipids in an immunomodulatory context. Mostly based on experiments on 
U937 cells, iPLA2 was found to play a role in both monocytic proliferation and apoptosis 
[21, 22, 213] LPC, as a product of iPLA2 activity in apoptotic U937 cells was shown to act 
as a clearance signal promoting macrophage phagocytosis [212]. An anti-inflammatory 
effect of LPC was also reported by Yan [307] experimenting on a murine sepsis model. 
LPC administration enhanced bactericidal activity in neutrophils and reduced TNF-α an 
IL-1β release upon LPS administration. The reduction in pro-inflammatory cytokine 
synthesis was mediated by a non-cholinergic mechanism involving the G2A LPC receptor 
[307]. The other major metabolite of iPLA2 enzymatic activity, archidonic acid (AA) is 
the precursor of prostaglandins, leukotrienes, and related compounds, which have 
important roles in inflammation and in the regulation of immunity [23, 61]. In an 
experimental model of sterile inflammation using mouse macrophage-like P388D1 cells, 
Akiba showed that prostaglandin D2 (PGD2), a metabolite of AA is significantly 
attenuated by iPLA2 antisense oligonucleotide [10]. PGD2 is reported to have anti-
inflammatory effects by inhibiting the recruitment of dendritic cells and neutrophils [184]. 
Under the influence of the anti-inflammatory cytokines IL-4 and IL-10 AA is also 
involved in the biosynthesis of anti-inflammatory lipid mediators such as lipoxins, 
resolvins and protectins, actively involved in the resolution of inflammation [254]. 
4.6 Cholinergic mediation of CCL3 activity 
To test for cholinergic mediation in our chemokine induced anti-inflammatory 
mechanism, we evaluated the inhibitory effect of CCL3 on IL-1β release against a panel 
of nicotinic antagonists. Indeed, mecamylamine, a general nicotinic blocker, as well as 
α-bungarotoxin and strychnine, antagonists of α7 and α9 nAChR subunits [171, 281], 
antagonized the CCL3-induced inhibition of IL-1β secretion from LPS-primed, 
BzATP-stimulated U937 cells. To further discriminate between the nAChR subunits 
involved, we made use of conotoxin-derived peptides [V11L; V16D]ArIB and RgIA4 
that specifically anatagonize nAChRs containing the α7 and α9/α10 subunits respectively. 
As both peptides blunted the effect of CCL3, we concluded that signal transduction in our 
proposed mechanism involves nAChR subunits α7 and α9/α10. Furthermore, the 
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inhibitory properties of the iPLA2β -derived mediator separated in the ultrafiltrate of 
conditioned medium were also antagonized by [V11L; V16D]ArIB and RgIA4. 
In a previous study, Zakrzewicz et al. [311] established the nicotinic receptor requirements 
for the anti-inflammatory effect induced by several iPLA2-metabolites, including G-PC 
and 1-palmitoyl-sn-glycero-3-phosphocholine, a member of the LPC class of 
phospholipids. By using the same panel of nAChR antagonists as applied in our study 
and corroborating the results with those of gene-silencing experiments using siRNA 
directed at specific nAChR subunits, it was shown that α9 and α10 are mandatory for the 
inhibitory mechanism mediated by this specific LPC and by G-PC. In contrast, α7 seemed 
to play no significant role in the cholinergically mediated inhibition of ATP-induced IL-
1β release by the two phospholipids. Therefore it is safe to conclude that the product of 
iPLA2β enzymatic activity released extracellularly downstream of the CCL3/CCR1 
interaction differs from 1-palmitoyl-sn-glycero-3-phosphocholine and G-PC, as the α7 
subunit is mandatory for its inhibitory effect. In a similar manner, ACh, nicotine and PC 
require all three receptor subunits (α7, α9 and α10) in order to inhibit ATP-induced IL-1β 
by monocytes [106, 233, 311]. It is to be noted that α9 is present in each of these examples, 
but regardless of the combination of nAChR subunits the effect remains a clear inhibition 
of ATP-induced IL-1β release in LPS-primed BzATP stimulated human monocytes. 
The question of how nAChR activation leads to inhibition of  ATP-induced IL-1β release 
is not clearly answered. It has been shown that in myenteric neurons, nicotinic ACh 
receptors can functionally interact with ATP-sensitive P2XRs by forming a heteromeric 
complex, in which the function of the partner receptor is altered [60]. nAChRs are 
canonically described as ionotropic receptors that upon activation by an agonist induce 
rapid increase in membrane permeability to Na+, K+ and Ca2+. By using patch-clamp 
experiments to monitor ion currents across the celluar membrane, it was shown that PC 
does not provoke any ion changes at the nAChRs in U937 cells and therefore 
metabotropic signaling is responsible for the inhibition of the P2X7R function [233]. In 
support of the metabotropic signaling of nAChRs it has been shown that the cytoplasmatic 
loop of certain nAChR subunits can interact with G proteins that might account for further 
signal transduction [140]. 
The matter of whether metabotropic or ionotropc signaling downstream of nAChRs was 
responsible for CCL3-induced inhibition ATP-dependent IL-1β release was not further 
pursued. We did verify whether the inhibitory effect of CCL3 on IL-1β synthesis was 
preserved in case of ATP-independent inflammasome activation. For this purpose we 
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made use of nigericin, a toxin produced by Streptomyces hygroscopicus, that forms pores 
in the cell membrane, leading to a depletion of intracellular K+ that induces NLRP3 
inflammasome assembly in the absence of extracellular ATP [93]. Nigericin-induced 
secretion of IL-1β was not reduced by CCL, supporting our assumption that CCL3 
triggers a mechanism that is specific for ATP-dependent inflammasome activation. 
Together, these results are in line with the idea, that chemokine signaling triggers a 
recently described mechanism involving activation of metabotropic functions of 
noncanonical nAChR containing subunits α7 and α9/ α10 that inhibit P2X7R signaling 
and, consequently, BzATP-induced release of IL-1β.  
4.7 Limitations of the study and perspectives for future research 
This study has several limitations, and certainly, more research is needed to substantiate 
the intriguing concept that chemokines attracting monocytes inhibit ATP-mediated 
inflammasome activation. Here, we only investigated chemokines CCL3, CCL4, and 
CCL5 with a focus on CCL3. The concept should be confirmed for other relevant 
chemokines involved in monocyte chemotaxis, especially for CCL2 that is regarded as 
the main attractant of human monocytes.  
Further, we used the monocytic cell line U937 as a model for human blood monocytes in 
most experiments. These cells were chosen as they possess the cholinergic control 
mechanism of IL-1β release typical for human blood monocytes [106, 267]. U937 cells, 
however, secrete very low amounts of IL-1β in response to ATP in comparison to primary 
human and mouse cells. Therefore, we corroborated the inhibitory potential of CCL3 on 
IL-1β release by primary human PBMCs in vitro. The levels of IL-1β released upon 
stimulation of the same amount of cells with the same BzATP concentration (100 µM) 
reached a median of 3.6 ng/ml in experiments using primary cells and of 38 pg/ml when 
using U937 cells. The LPS concentration used for priming primary cells was considerably 
lower than that used for U937 cells, as previous experience showed that PBMCs are 
primed through the process of isolation itself, especially during gradient centrifugation 
and adherence to tissue culture dishes [106, 114, 136]. The molecular mechanism undelying 
the inhibitory effect of chemokines on IL-1β secretion is therefore intact in the U937 cell 
line, just as in primary cells, with notable quantitative differences in the LPS 
concentration required for priming and the secreted IL-1β levels. In support of this 
hypothesis, the experiments accounting for the involvement of iPLA2β and nAChR in the 
proposed mechanism should be reproduced using primary cells. 
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Going one step further, the inhibitory mechanism should be tested in vivo, where 
difficulties are bound to arise due to the intricacies of the chemokine system. As mice are 
the in vivo experimental model of choice, several differences in the murine chemokine 
systems are to be noted when compared to the human counterpart. Refering strictly to 
chemokine and chemokine receptors acting on monocytes and monocyte-derived cells, 
CCL13 also known as MCP-4, binding to chemokine receptors CCR1, CCR2 and CCR3 
has been identified in humans but not in mice [178]. CCL14 that is 46% identical in amino 
acid composition to CCL3 and CCL4 and is involved in monocyte activation is also 
human specific and lacks a murine counterpart [18]. Conversely CCL12 or MCP-5 is a 
chemokine binding to CCR2 identified in mice but not in humans [178].   
In addition, there are numerous open questions regarding the details of the proposed novel 
signal transduction mechanism, including the identification of the bioactive soluble 
factor(s) activating nAChR and the signaling mechanisms down-stream of nAChR. 
4.8 Biological and clinical relevance  
Inflammasome activation, resulting in the production of inflammasome-dependent pro-
inflammatory mediators is a double-edged sword that is required for host defense against 
infections but is also associated with the risk of inducing life-threatening SIRS. A strict 
quantitative, temporal and spacial control of IL-1β release, translating into the right 
amount of secreted IL-1β, at the right time, into the appropriate biological compartment 
might be at least partially responsible for whether the balance tips towards the resolution 
of inflammation or SIRS. Release of monocytic IL-1β to the blood stream is expected to 
be of limited use as the cytokine is swept away from the site of inflammation, but in 
contrast, the risk of inducing harmful systemic inflammation should be higher. In this 
study, we demonstrate that chemokines block the ATP-dependent IL-1β release by blood 
monocytes, a mechanism that would contribute to the prevention of systemic 
inflammation. In contrast, release of IL-1β by inflammatory macrophages within the 
tissue would fight against local infections causing less systemic effects. We expect that 
IL-1β can be released to inflamed tissue by macrophages despite high local chemokine 
levels, as pathogens induce inflammasome activation by several ATP-independent 
mechanisms that are probably not sensitive to chemokines [147, 268, 290]. Furthermore it 
is well known that upon maturation into tissue macrophages, human monocytes undergo 
a reconfiguration of the chemokine receptors expressed on their surface, with a loss of 
CCR2 expression [73]. It is also known that polarized tissue macrophages differ in patterns 
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of cytokine production and regulation of pro- and anti-inflammatory components of the 
IL-1 system [64]. The low oxygen concentrations characterizing the inflammatory tissue 
milieu also affects how macrophages respond to chemokines [279]. There are therefore 
several reasons to hypothesize that chemokines do not inhibit the ATP-dependent IL-1β 
release of tissue macrophages, a topic that certainly deserves more investigation.  
A number of components involved in our proposed mechanism of chemokine induced 
IL-1β inhibition have already been targeted for the development of anti-inflammatory 
drugs, resulting in a series of studies ranging from in vitro to approved pharmaceutics, as 
illustrated in Table 10. In the case of  selective CCR1-antagonists, the encouraging results 
obtained in preclinical models of MS, rheumatoid arthritis (RA) or heart transplantation 
failed to be reproduced by clinical trials. The argument most frequently brought forward 
to explain the discrepancy in results was incomplete receptor coverage [57, 148]. 
Only a few iPLA2 inhibitors have been developed up to date, since the importance of the 
enzyme in a number of medical pathologies has only recently come to focus. An anti-
inflammatory effect was suggested by in vivo studies on murine models of MS [125]. 
Clinical trials have not yet been initiated. Relying on cholinergically mediated anti-
inflammatory effects selective α7nAChR agonists have been developed with promising 
results in experimental clinical trials. No doubt, the most successful of the below listed 
componds are the ones targeting IL-1β, that partially have already been approved for 
clinical use in a spectrum of autoinflammatory and systemic inflammatory conditions. 
There are therefore reasons to believe that the immunemodulatory effect of CCL3 might 
also be used to develop novel therapeutic agents. 
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Target Compound Mechanism 
of action 
Addressed 
pathology 
Type of 
study 
Status Ref. 
CCR1 
BX 471 
 
CCR1-
antagonists 
MS, 
psoriasis 
phase II 
clinical 
trials 
no efficacy 151, 209 
MLN 3897 RA no efficacy 287 
CP-481, 715 RA no efficacy 42 
AZD4818 COPD no efficacy 137 
CCX354 RA ongoing 57 
C-4462 RA no efficacy 191  
C-6448 MS no efficacy 191  
iPLA2 
 
FKGK11 
iPLA2-
inhibitors 
 
EAE 
in vivo, 
murine 
model 
 
slows disease 
progression 
 
125 
FKGK18 diabetes 
in vivo, 
murine 
model 
prevents beta-
cell apoptosis 
 
272 
GK 187 none 
in vitro, 
micelle-
based 
assays 
 158 
nAChR 
nicotine 
 
nAChR 
agonist 
experimental 
endotoxemia 
phase I 
clinical 
trial 
attenuated 
febrile response 303 
GTS-21 
 selective- α7nAChR 
agonists 
 
experimental 
endotoxemia 
phase I 
clinical 
trial 
no efficacy 143 
PNU-282987 acute lung injury 
in vivo, 
murine 
model 
anti-
inflammatory 85 
IL-1β 
Anakinra 
receptor 
antagonist for 
IL-1RI 
RA 
CAPS 
Still’s 
disease 
approved anti-inflammatory 66 
Rilonacept soluble IL-1 receptor CAPS approved 
anti-
inflammatory 
195, 
263 
Canakinumab 
neutralizing 
anti-IL-1β 
IgG1 mAb 
CAPS approved anti-inflammatory 
40,  
69 
Gevokizumab 
neutralizing 
anti-IL-1β 
IgG2 mAb 
RA 
phase II 
clinical 
trial 
anti-
inflammatory 54 
NLRP3 
inflammasome 
CY-09 
inhibitor of 
NLRP3 
ATPase 
activity 
 
CAPS 
Type 2 
diabetes 
in vivo, 
murine 
models 
anti-
inflammatory 119 
OLT1177 
specific 
NLRP3 
inihibition 
gouty arhritis 
in vivo, 
murine 
models 
anti-
inflammatory 164 
Table 10: Compounds targeting components related our proposed chemokine induced anti-inflammatory 
mechanism, their mechanism of action and achieved results in preclinical and clinical trials. CCR1, C-C 
motif chemokine receptor 1; MS, multiple sclerosis; RA, rheumatoid arthritis; COPD, chronic obstructive 
pulmonary disease; iPLA2, calcium-independent phospholipase A2; EAE, experimental autoimmune 
encephalomyelitis; nAChR, nicotinic acetylcholine receptor; IL-1β, interleukin-1β; IL-1RI, interleukin-1 
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receptor, type I; CAPS, cryopyrin-associated autoinflammatory syndrome; NLRP3, NOD-like receptor 
family, pyrin domain containing 3. 
 
4.9 Conclusion 
Our results are in line with the hypothesis that CCL3, CCL4, and CCL5 inhibit BzATP-
induced maturation and release of IL-1β by LPS-primed monocytic cells. CCL signaling 
seems to depend on binding to cognate CCR, activation of iPLA2β, and release of soluble 
agonists of nAChR containing subunits α7 and α9/α10 that inhibit IL-1β release (Figure 
19). It has been shown before that activation of monocytic nAChR is a potent way to 
inhibit ATP- induced activation of P2X7R, inflammasome activation, and release of IL-1β. 
The control of inflammasome activation in despite of the presence of ATP is of 
outstanding clinical interest. A better understanding of the underlying mechanisms might 
lead to the development of therapeutic strategies for the prevention and treatment of 
inflammatory diseases. With all due caution, we suggest a novel CCL-induced anti-
inflammatory triple-membrane-passing signaling pathway inhibiting premature 
inflammasome activation in monocytes in response to extracellular ATP.  
This mechanism might reduce trauma-induced release of IL-1β into the circulation and 
thereby prevent sterile SIRS. As trauma is often associated with infection, infiltrating 
monocytes/macrophages and local IL-1β release at the site of inflammation are desirable. 
As PAMP-induced inflammasome activation is typically ATP-independent, local secre- 
tion of inflammasome-dependent cytokines by infiltrating monocytes/macrophages 
should be enabled, in despite of the presence of chemokines. 
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5 Graphical summary 
 
Figure 19: Schematic presentation of the proposed mechanism. The binding of extracellular ATP to P2X7R 
on LPS-primed human monocytic U937 cells results in formation of a multiprotein complex called 
inflammasome that, in turn, activates caspase-1. Caspase-1 catalyzes the proteolytic maturation of pro-
IL-1β and enables the release of mature, bioactive IL-1β. We propose that, chemokine CCL3 binding to its 
cognate CCR1 chemokine receptor, on the surface of LPS-primed U937 cells leads to downstream 
activation of calcium-independent phospholipase A2β (iPLA2β) and the secretion of a small agonist of 
nicotinic acetylcholine receptors (nAChR). Stimulation of nAChR containing subunits α7 and α9/α10 
inhibits P2X7R function and, hence, maturation and secretion of ATP-dependent IL-1β. It is still unclear if 
nAChR subunits of monocytic cells actually form conventional pentamers as shown in the schematic 
drawing 
Fig. 6
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6 Summary 
ATP and chemokines are among the first inflammatory mediators that can enter the 
circulation via damaged blood vessels at the site of injury, leading to an activation of the 
host’s immune response. The main function of chemokines is leukocyte mobilization, 
guiding immune cells towards the injured tissue along a chemotactic concentration 
gradient. In monocytes, ATP typically triggers inflammasome assembly, a multiprotein 
complex necessary for the maturation and secretion of IL-1β. IL-1β is a potent 
inflammatory cytokine of innate immunity, essential for pathogen defense. However, 
excessive IL-1β may cause life-threatening systemic inflammation. Here, we hypothesize 
that chemokines control ATP-dependent secretion of monocytic IL-1β, by engaging a 
cholinergic signaling pathway. 
LPS-primed human monocytic U937 cells were treated with chemokines in the presence 
or absence of nAChR antagonists or iPLA2β inhibitors and concomitantly stimulated with 
the P2X7 agonist BzATP. IL-1β concentration was determined in the cell culture 
supernatants. Silencing of the chemokine receptor and iPLA2b gene expression was 
achieved by transfecting cells with the appropriate siRNA. 
CCL3, CCL4, and CCL5 dose-dependently inhibited BzATP-stimulated release of IL-1β, 
whereas CXCL16 was ineffective. The effect of CCL3 was confirmed for primary 
mononuclear leukocytes. The inhibitory effect of CCL3 was blunted after silencing CCR1 
or iPLA2β gene expression by siRNA and was sensitive to antagonists of nAChRs 
containing subunits α7 and α9/α10. U937 cells secreted small factors in response to CCL3 
that mediated the inhibition of IL-1β release.  
We suggest that CCL chemokines inhibit ATP-induced release of IL-1β from U937 cells 
by a triple-membrane-passing mechanism involving CCR, iPLA2, release of small 
mediators, and nAChR subunits α7 and α9/α10. We speculate that whenever chemokines 
and ATP enter the circulation concomitantly, systemic release of IL-1β is minimized.
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Zusammenfassung 
ATP und Chemokine gehören zu den ersten Entzündungsmediatoren, die bei 
Verletzungen in den Blutstrom gelangen und zu einer Aktivierung des Immunsystems 
führen. Chemokine sind chemotaktisch wirksame Botenstoffe, die Leukozyten entlang 
von Konzentrationsgradienten zum entzündeten Gewebe führen. ATP löst in Monozyten 
typischerweise die Bildung des Inflammasoms aus, ein Multiproteinkomplex, der zur 
Reifung und Freisetzung von IL-1β benötigt wird. IL-1β ist ein potentes pro-
inflammatorisches Zytokin, das bei der Infektabwehr eine zentrale Rolle spielt. Hohe 
systemische IL-1β-Spiegel lösen jedoch das lebensbedrohliche systemische SIRS aus. 
Wir überprüfen hier die Hypothese, dass Chemokine die ATP-induzierte 
IL-1β-Freisetzung aus Monozyten kontrollieren, indem sie einen kürzlich von uns 
beschriebenen cholinergen Signalweg aktivieren. 
Humane U937-Zellen wurden mit LPS vorstimuliert und mit ATP aktiviert. Gleichzeitig 
mit ATP wurden Chemokine, nAChR-Antagonisten oder Inhibitoren der iPLA2 
eingesetzt. Die IL-1β-Konzentration wurde im Zellkulturüberstand mittels ELISA 
bestimmt. Die Herunterregulation der Expression von Chemokinrezeptoren und der 
iPLA2 erfolgte durch Transfektion spezifischer siRNA. 
CCL3, CCL4, und CCL5 inhibieren dosisabhängig die ATP-induzierte 
IL-1β-Freisetzung, während CXCL16 unwirksam ist. Der Effekt von CCL3 konnte an 
frisch isolierten primären peripheren mononukleären Blutzellen bestätigt werden. Die 
inhibitorische Wirkung von CCL3 hängt vom Chemokinrezeptor CCR1, von der iPLA2 
und von den nAChR-Untereinheiten α7, α9 und α10 ab. U937-Zellen sezernierten nach 
Stimulation mit CCL3 niedermolekulare bioaktive Faktoren, die die Inhibition ATP-
abhängigen IL-1β-Freisetzung vermitteln. 
In menschlichen Monozyten hemmen CCL-Chemokine die ATP-induzierte IL-1β-
Freisetzung über einen Mechanismus, der dreimal die Cytoplasmamembran überspannt 
und über Chemokinrezeptoren, iPLA2 und nAChR vermittelt wird. Wir vermuten, dass 
immer wenn CCL-Chemokine und ATP zusammen in den Blutstrom gelangen, die 
systemische Freisetzung von IL-1β und damit der Gefahr eines SIRS reduzier
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